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1. Introduction 
 
Tumor cells display and depend on increased metabolic activity to sustain 
proliferation. Among other pathways glycolysis is strongly elevated. Inhibition of this 
vital metabolic pathway is a fairly new approach and several anti-glycolytic drugs are 
currently under investigation in clinical trials (1, 2). However, beside tumor cells other 
organs and tissues also rely on glucose metabolism and the suppression of this 
pathway might result in adverse side effects. In particular, activated T lymphocytes 
show a similar metabolic phenotype compared to cancer cells. Thus, anti-glycolytic 
drugs might impede T cell function. As T cell infiltration and activation are important 
for the prognosis of tumor patients, preservation of T cell function is crucial (3). The 
link between glucose metabolism and T cell function has been mainly investigated in 
the murine system and data on the human system are rather sparse and 
contradictory. However, analyzing the importance of glucose metabolism and the 
impact of glycolytic inhibitors on human T cell function is a prerequisite for the 
development of treatment strategies selectively affecting tumor cells.   
 
1.1 Tumor cells 
1.1.1 Characteristics of a tumor cell 
  
In 2000 Hanahan and Weinberg defined the main attributes of neoplastic cells – the 
well-known “Hallmarks of Cancer” (4). 
The hallmarks include (i) a sustained proliferation and cell growth by increased 
receptor sensitivity, autocrine hormone secretion or constitutive pathway activation; 
(ii) evasion of growth suppressors by loss of tumor suppressor genes such as 
retinoblastoma 1 (RB1) or tumor protein p53 (TP53) or corruption of the anti-
proliferative effect of the transforming growth factor β (TGFβ); (iii) resistance to cell 
death via increase of anti-apoptotic (e.g. Bcl-2) and decrease of pro-apoptotic 
proteins (e.g. Bax, Bak); (iv) enabling of replicative immortality by the up-regulation of 
the enzyme telomerase, which elongates replication-limiting, telomeric DNA-endings; 
(v) induction of angiogenesis to assure removal of waste products and supply with 
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essential nutrients and oxygen; (vi) activation of invasion and metastasis via down-
regulation of adhesion molecules and genetic transition into migrating cells.  
In 2011 two emerging hallmarks were added by the authors: evasion of immune 
destruction and re-programming of energy metabolism (5). 
 
1.1.2 Tumor cell metabolism 
 
In the 1920s Otto Warburg, a German scientist, reported increasing lactic acid 
concentrations in tumor cell cultures, resulting from accelerated glucose metabolism 
(6). This physiological process is well known from muscle cells switching from Krebs´ 
cycle (= tricarboxylic acid cycle; TCA cycle) derived energy production to glucose 
fermentation under oxygen limitation. Surprisingly, Warburg demonstrated, that tumor 
cells exhibited the same metabolic phenotype even in the presence of oxygen (= 
Warburg effect, aerobic glycolysis). Nowadays, this feature is used in diagnosis to 
detect tumor cells by fluorodeoxyglucose traced positron emission tomography–
computed tomography (FDG-PET/CT) (7). 
The highly glycolytic state is achieved by up-regulating the expression of enzymes 
linked to glycolysis. Hexokinase (HK), the first enzyme in the glycolytic pathway, 
and other glycolytic key enzyme such as phosphofructokinase (PFK) or lactate 
dehydrogenase (LDH) are elevated on transcriptional and protein level (8, 9). In a 
variety of tumors LDH-A is upregulated and its expression negatively correlates with 
patient survival (10). LDH-A degrades pyruvate to lactate thereby regenerating NAD+ 
which is necessary to maintain the glycolytic flux (11).  
Besides an up-regulated expression, also an altered activity, reaction rate and 
substrate specificity of glycolytic enzymes is observed and tumor specific isoforms 
of different enzymes are detected as a result of alternative splicing processes after 
transcription. For example in normal cells HK is expressed as isoform HK-I. Tumor 
cells, however, express the isoform HK-II, which in contrast is not negatively 
regulated by its product glucose-6-phosphate thus ensuring a continued glycolytic 
flux. Furthermore, HK-II is bound to the outer mitochondrial membrane thus (i) 
enabling an immediate access to mitochondrially produced ATP and (ii) preventing 
the apoptosis inducing release of cytochrome c (11, 12). Non-transformed cells 
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express the M1 isoform of the pyruvate kinase (PKM1). However, almost every tumor 
cell expresses the subtype M2 (PKM2), which has intrinsically a lower enzymatic 
activity and is impeded by different kinases. Consequently, glycolytic intermediates 
accumulate and promote the anabolic metabolism by flux into downstream pathways 
such as the pentose phosphate pathway. In addition PKM2 is described as a co-
factor for transcription (11, 13). 
Furthermore, the expression of transporters linked to glucose metabolism is 
increased in tumor cells. To ensure high intracellular glucose concentrations, the 
amount of insulin-independent glucose transporters (GLUT) is elevated on  
transcriptional level but also by increased surface trafficking of cytosolic transporters 
(14, 15). The transport of glucose across the lipid membrane by GLUT is energy 
independent. Especially GLUT1, GLUT3 and GLUT4 show a high affinity to glucose 
and ensure a sufficient glucose flux into cancer cells even under low-glucose 
conditions (11, 16). Accordingly, overexpression of GLUT1 has been related to poor 
prognosis in tumor bearing patients (17). The expression of monocarboxylate 
transporters (MCT) is also up-regulated in a variety of tumors (18). MCTs belong to 
the solute carrier 16 (SLC16) family (19) and transport lactate across the plasma 
membrane in co-transport with a proton thereby maintaining the intracellular pH and 
cell homeostasis (20). Notably, the MCTs bidirectionally transport substrates 
depending on the intra- and extracellular concentration gradients of protons and 
substrates as lactate (21). The most common monocarboxylate transporters in 
cancer cells are MCT1 and MCT4: While MCT1 is found in many tissues and 
transports a wider range of substrates (e.g. lactate, benzoate, butyrate), MCT4 in 
contrast is mainly expressed in highly glycolytic cells such as tumor cells. 
Accordingly, MCT4 exhibits higher Km values (MCT4: Km = 20 mM) compared to 
other members of the MCT family (MCT1: Km = 5 mM) enabling a sufficient export of 
lactate even under conditions of extensive production and preventing loss of pyruvate 
across the cell membrane (18, 22). Interestingly, MCT1 and MCT4 expression varies 
even within a tumor: while hypoxic areas preferentially express MCT4 to release 
lactate, normoxic regions take up and metabolize the monocarboxylate via MCT1 
(23, 24). Furthermore, MCT surface expression is regulated by the matrix 
metalloproteinase inducer basignin (= CD147), which is required for the transport to 
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and insertion of MCTs into the cell membrane. Its activation in turn promotes matrix 
degradation, invasion and metastasis (25).  
Initially, the Warburg phenotype was attributed to mitochondrial disorders, however 
even increased mitochondrial content and energy production have been observed in 
different tumors (26–28). Other reasons for the switch to glycolysis are currently 
discussed. Glycolysis yields only two molecules ATP from one molecule glucose 
compared to 36 molecules ATP gained by mitochondrial oxidative phosphorylation 
(OXPHOS). However, despite the lower yield of ATP, glycolysis is the most time-
effective and least energy demanding process by which a cell can gain additional 
energy (29). When energy production is covered by glycolysis, the intermediates of 
the TCA cycle can be used for the generation of building blocks.  
Thus accelerated glycolysis is necessary to accomplish the high energy demand of 
proliferating cells required for the production of biomass and to ensure DNA 
replication and cell division. Moreover, glycolytic intermediates are required for the 
generation of building blocks as shown in figure 1 (30).  
The flux of glucose-6-phosphate to the pentose phosphate pathway (PPP) facilitates 
the synthesis of nucleotides (ATP, GTP, TTP, CTP) being essential for DNA 
replication and RNA transcription. Furthermore, NADP+ is reduced to NADPH, which 
is important for the replenishment of the antioxidant glutathione and serves as a 
reducing equivalent for lipid biosynthesis. Glyceraldehyde-3-phophate, 3-
phosphoglycerate and acetyl-CoA are the carbon sources for lipid biosynthesis. In 
addition, 3-phosphoglycerate is essential for amino acid biosynthesis of glycine and 
cysteine via serine (30).  
Additionally, proliferating cells utilize the amino acid glutamine as alternative carbon- 
and essential nitrogen-source. Moreover, the degradation products of glutaminolysis 
replenish the pool of mitochondrial intermediates (= anaplerosis) and thereby - 
replacing glucose - maintain mitochondrial energy production. Vice versa, substrates 
of the TCA cycle are transported to the cytosol (= cataplerosis) and serve as 
precursors of the amino acids proline and arginine. Moreover, the intermediates α-
ketoglutarate (αKG) and citrate are converted into acetyl-CoA by cytosolic ATP-
citrate lyase (ACL) and used as the main building block of cholesterol and other lipids 
(figure 1).    
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First described in solid tumors, these alterations in metabolism are also observed in 
leukemia and lymphoma cells (31, 32)  
 
 
 
 
 
 
Figure 1. Glucose and glutamine metabolism of neoplastic cells 
(modified after Lunt et. al, Annual review of cell and developmental biology, 2011 (30)) 
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1.1.3 Regulation of tumor cell metabolism 
 
As described above, the Warburg effect supports tumor growth and proliferation by 
providing essential building blocks and ATP. Mitogenic activation normally depends 
on the interaction of growth factors and their receptors. In cancer cells, however, 
pathways downstream of those receptors can be constitutively activated in the 
absence of extracellular stimuli by mutations, enhanced intrinsic activity or 
elimination of negative regulators. Moreover, it has been shown, that tumor 
suppressors and proto-oncogenes directly activate cell metabolism.  
 
1.1.3.1 The PI3K/Akt/mTORC1 pathway 
 
The PI3K/Akt/mTORC1 pathway is a complex signaling network and highly activated 
in many tumors (33). Phosphatidylinositol-3-kinase (PI3K), a lipid kinase, is activated 
by receptor protein tyrosine kinases (RPTK) and G protein coupled growth factor 
receptors like epidermal growth factor receptor (EGFR) or insulin-like growth factor 
receptor (IGFR). Upon activation PI3K phosphorylates phosphatidylinositol-2-
phosphate (PIP2) to phosphatidylinositol-3-phosphate (PIP3). Proteins expressing 
pleckstrin homology domains (PH) such as 3-phosphoinositide dependent kinase 1 
(PDK1) bind to PIP3 and activate the serine threonine kinase Akt by conformational 
change and phosphorylation. Conversely, phosphatase and tensin homolog (PTEN) 
dephosphorylates PIP3 to PIP2 and prevents overstimulation of Akt.     
Akt is expressed in three different isoforms: Akt1, Akt2 and Akt3. All of them 
modulate numerous regulators of cell survival, cell cycle progression and metabolism 
on a transcriptional or post-translational level (34). By phosphorylation Akt increases 
the activity of the rate-limiting glycolytic enzyme HK (35). Moreover, the association 
of HK with the outer mitochondrial membrane (as described above) is promoted (36). 
The stimulation of PFK2 results in an accumulation of the allosteric PFK1 activator 
fructose-2,6-bisphosphate thus indirectly enhancing glycolysis (37). Glucose uptake 
is supported by trafficking of intracellularly stored GLUT1 to the plasma membrane, 
even though underlying mechanisms have not yet been fully understood (38). In 
addition, Akt phosphorylates and therewith inactivates pro-apoptotic factors such as 
Introduction 
 
7 
 
Bad, procaspase-9 or transcriptional factors of the death ligand Fas (39, 40). 
Importantly, Akt promotes the formation of the mammalian target of rapamycin 
complex 1 (mTORC1)(34). Besides the post-translational modulation also 
transcriptional effects are described: Akt and mTORC1 control the expression of 
almost all genes involved in glucose uptake (41) and glycolysis (42, 43) by the 
transcription factors HIF1α and c-Myc (see below). Akt activates the nuclear factor κB 
(NFκB) and the cyclic AMP response element-binding protein (CREB), both 
upregulating the expression of survival genes (44). Moreover, mTORC1 up-regulates 
the messenger RNA (mRNA) translation by the effector proteins S6 kinase 1 (S6K1) 
and the eukaryotic initiation factor 4E (eiF-4E)- binding protein 1 (4E-BP1) and 
accelerates the cellular turnover (45).  
  
1.1.3.2 Hypoxia inducible factor 1α (HIF1α) 
 
Different stimuli, such as Akt and mTORC1 activity, hypoxia or reactive oxygen 
species (ROS) inhibit the constant degradation of HIF1α by proteasomes. 
Dimerization with the constitutively expressed HIF1β protein leads to the activation of 
the HIF-complex. Upon heterodimerization the complex acts as a transcription factor 
on hypoxia-responsive elements (HREs) itself, but also regulates further transcription 
factors. Target genes upregulate glucose metabolism, cell differentiation and 
metastasis: activated HIF up-regulates GLUTs, glycolytic enzymes e.g. hexokinase 
(9) as well as LDH-A and pyruvate dehydrogenase kinase 1 (PDK1). This in turn 
restricts the uptake of glucose-derived pyruvate by mitochondria and decreases 
cellular respiration (46). As Ullah et al. show, MCT4 but not MCT1 is increased by 
HIF1α expression (47). Additionally, the vascular endothelial growth factor (VEGF) is 
an important target gene of the HIF-complex. VEGF induces angiogenesis and 
improves oxygen and nutrient supply, but also facilitates hematogenous metastasis 
of tumor cells. Furthermore, the matrix metalloproteinases 2 and 9 (MMP2, MMP9) 
are up-regulated and cell adhesion molecules (such as E-cadherin) down-regulated 
(48), which supports metastasis. There is evidence, that HIF promotes the de-
differentiation of cancer cells and prevents differentiation of progenitors (49, 50).     
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1.1.3.3 c-Myc amplification 
 
Myc is a transcription factor, which regulates the expression of a variety of human 
genes upon dimerization with the protein Myc-associated factor x (Max). Myc is the 
product of the c-Myc gene (cellular myelocytomatosis gene) and amplification is 
caused either by an activating mutation, by oncogenes inducing gene expression or 
by a decreased protein degradation as a result of an inefficient ubiquitination (51). 
Especially, the growth factor receptor-associated phosphorylation cascade Ras (rat 
sarcoma) – Raf (rat fibrosarcoma) – MEK (Mitogen/Extracellular signal-regulated 
kinase) – ERK (extracellular signal-regulated kinase) and the PI3K/Akt/mTOR 
pathway promote the induction of Myc expression (52). Amplified Myc results in the 
overexpression of glucose transporters and several glycolytic enzymes such as HK, 
PFK, LDH-A and PDK. Myc also initiates the alternative splicing of pyruvate kinase to 
PKM2 (53). Beyond that, Myc supports the upregulation of glutaminolysis by 
increasing the expression of amino-acid transporter 2 (ASCT2) and glutaminase 
(GLS), catalyzing the reaction of glutamine to glutamate (13, 52). As a consequence 
cells become glutamine dependent, which intriguingly leads to apoptosis in case of 
glutamine withdrawal in Myc overexpressing cells (54). Myc also stimulates ribosome 
biogenesis and increases nucleotide biosynthesis by expression of several PPP 
enzymes (52). Myc regulates cell cycle progression by increased transcription of 
cyclin dependent kinases (Cdks), cyclins or associated transcription factors like E2F 
and the antagonism of the cell cycle inhibitors p21Cip and p27Kip (55). Cyclins enable 
the transition of G1- (gap 1 phase) to S-phase (synthesis phase) in the cell cycle and 
support proliferation (56). 
 
1.1.3.4 Loss of p53 expression 
 
p53, also known as “the guardian of the genome”, is a tumor suppressor 
accumulating intracellularly as a consequence of DNA damages like strand brakes. 
Thereupon, DNA repair systems are activated while cell cycle is arrested. Failure of 
DNA repair leads to increasing p53 levels and the induction of apoptosis by caspases 
(57). Moreover, p53 also affects cell metabolism by blocking glycolysis via the protein 
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TIGAR (TP53-induced glycolysis and apoptosis regulator), which impedes the 
enzymatic reaction of fructose-6-phosphate to fructose-2,6-bisphophate (58). On the 
other hand p53 enhances mitochondrial enzyme synthesis as cytochrome c oxidase 
2 (SCO2) expression, which in turn increases oxidative phosphorylation (OXPHOS) 
(59, 60). A loss of function mutation in the p53 tumor suppressor gene promotes cell 
cycle and enhances glycolysis (8). 
 
1.1.4 Inhibition of tumor glucose metabolism – a promising therapeutic 
strategy? 
 
As tumor cells - in contrast to non-malignant cells – display a highly elevated 
glycolysis, inhibition of this metabolic pathway is an emerging therapeutic strategy. 
Glycolytic restriction affects tumor cells in many ways: (i) reduced energy supply 
resulting in increased (chemo-/radio-) therapeutic sensitivity (61–63), (ii) growth 
inhibition due to lack of necessary building blocks and (iii) diminished extracellular 
lactate accumulation. There is growing evidence that lactic acid is not only the end 
product of aerobic glycolysis but also represents an alternative fuel for respiring 
tumor cells. Tumor-associated cells, such as fibroblasts, can also metabolize lactate 
instead of glucose, which prevents a competition for nutrients between tumor, tumor-
associated and immune cells (23, 64). Furthermore, the acidic tumor milieu alters 
immune cell function and the extracellular matrix and promotes invasion and 
metastasis (65). Numerous studies showed a correlation between pH level and drug 
resistance of tumor cells (20). As shown by Fischer et al., high extracellular lactic 
acid concentration blocks the secretion of lactate by activated human T cells. This 
results in an impaired T cell function thereby contributing to the immune escape of 
tumor cells (66, 67). Additionally, lactic acid decreases the ability of monocytes to 
produce the pro-inflammatory cytokine tumor necrosis factor alpha (TNFα) playing an 
important role in the anti-tumor immune response (68). Furthermore, Colegio et al. 
demonstrated, that tumor-derived lactate is taken up by tumor associated 
macrophages (TAMs) and leads to an increased expression of the vascular 
endothelial growth factor (VEGF) and arginase 1 - both tumor promoting factors (69). 
This implies, that lactate acts not only as an immunosuppressor, but is capable to 
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recruit and support pro-tumorigenic immune cells fostering tumor growth, 
maintenance and metastasis (70).      
Interfering with the glycolytic pathway is possible on different levels: (i) on the level of 
signal transduction and transcription and (ii) on the protein level of enzymes and 
transporters of the metabolic pathway itself. 
(i) Signaling pathways involved in the regulation of metabolism are already targeted 
by many substances resulting in an interrupted growth and proliferation or even the 
induction of apoptosis in tumor cells: 
Growth factor receptor: The monoclonal antibody cetuximab impedes EGF-receptor 
mediated growth signaling via the PI3K/Akt/mTORC1 pathway, which is successfully 
applied in the treatment of colorectal cancer (71, 72). 
PI3K/Akt: Akt inhibition via perifosine in combination with other Akt inhibitors is in the 
focus of new therapeutic strategies for T-ALL (73). 
mTORC1: rapamycin targets mTORC1 and thereby diminishes its transcriptional 
effects on genes up-regulating glycolysis. Additionally, the antidiabetic drug 
metformin induces AMP-kinase (AMPK), which indirectly inhibits mTORC1 (74).  
HIF1: hypoxia and other factors stabilize the transcription factor subunit HIF1α (as 
shown above). For activation necessary dimerization with the β-subunit can be 
blocked by the drug acriflavine (75). 
 
(ii) Glucose metabolism can be targeted on several steps and inhibitors of glycolytic 
enzymes as well as of transporters are currently under investigation (figure 2). The 
first step in glucose metabolism is the uptake of glucose by different transporters. 
GLUT1, overexpressed in many tumor cells (14), is targeted by the drugs phloretin 
(76) and fasentin (77). Furthermore, hexokinase is impeded by various substances 
such as lonidamine (78), 3-bromopyruvate (79) or 2-deoxyglucose (2DG) (11, 80). 
2DG, a glucose analogue, is converted into 2-deoxyglucosephosphate (2DG-P), 
which cannot be further metabolized. Its accumulation leads to a feed-back inhibition 
and a subsequent glycolytic arrest (81). 2DG application results in a release of 
hexokinase II (HK II) from the outer mitochondrial membrane, affecting the integrity of 
mitochondria and their function (63, 82). Similar effects are achieved by the inhibition 
of phosphofructokinase and pyruvate kinase (11). Another approach is the blockade 
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of pyruvate dehydrogenase kinase 1 (PDK1) by dichloroacetate (DCA), which 
reduces its inhibitory effect on pyruvate dehydrogenase (PDH). This results in a 
regained flux of pyruvate into the TCA cycle, increased OXPHOS and a drop in 
lactate excretion (83). Next, lactate dehydrogenase (LDH) is impeded by FX11 and 
oxamate, which leads to ATP depletion and a reduced chemotherapeutic drug 
resistance (84, 85). Additionally, the close cooperation of LDH with the transcription 
factor Oct-4 (Octamer binding transcription factor 4) is compromised (86). Blockade 
of monocarboxylate transporters MCT1 and MCT4 has anti-tumorigenic effects by 
blocking lactate efflux which results in an intracellular acidification and cell death (87, 
88). A specific inhibitor of MCT1 (AR-C155858) was developed by AstraZeneca (89) 
and effectively blocks growth of transformed fibroblasts (90). Another MCT1 inhibitor 
(AZD3965) induces cell death of breast cancer and Burkitt lymphoma cell lines (88). 
Importantly, efficient inhibition of glycolysis implies simultaneous blockade of both 
MCT transporters (22, 90).  
Recently it has been shown that diclofenac, a non-steroidal anti-inflammatory drug 
(NSAID), is a potent glycolytic inhibitor in several tumor cells (melanoma and 
histiocytoma cells). The observed effects are independent of cyclooxygenase (COX) 
inhibition, as neither the unspecific COX-inhibitor aspirin nor the selective COX-2 
inhibitor NS-398 showed an effect on proliferation and lactate production (91). 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At first glance, inhibition of glycolysis seems to be a selective therapeutic strategy for 
tumor cells. However, many of the above mentioned targets are ubiquitously 
expressed in non-malignant cells (e.g. GLUT and glycolytic enzymes), so that 
blockade of this metabolic phenotype may hit other glucose-dependent cells.  
Several studies show a comparable metabolic switch in T lymphocytes upon 
activation (92, 93), which raises concerns of a reduced immunofunction under anti-
glycolytic treatment. As T cell infiltration and activation in the tumor tissue are 
correlated with a better prognosis (3, 94, 95), anti-glycolytic drugs might compromise 
T cell function thus negatively affecting patient outcome. However, the inhibition of 
glycolysis results in reduced tumor cell proliferation, viability and concomitantly 
lowered extracellular lactic acid concentration. Consequently, the anti-tumor immune 
response might be improved. In summary, the overlapping metabolic profile and 
complex interactions between tumor and immune cells challenge the application of 
anti-glycolytic therapies for tumor therapy.   
 
 
Figure 2. Targets and appropriate anti-metabolic compounds already used in treatment of tumors 
(by Tennant et al., Nature Reviews Cancer, 2010 (80), reprinted by permission from Macmillan Publishers Ltd: 
Nature Reviews Cancer, © 2010)  
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1.2 Activation, effector function and metabolism of human T lymphocytes 
 
The human immune system is challenged by a variety of different pathogens. 
Besides the unspecific response of the innate immune system, a successful defense 
against infections or degenerated cells depends on the adaptive immune response. 
Naive cells surveil the tissue and blood using a wide variety of different and unique 
recognition receptors and, upon activation, undergo massive clonal expansion to 
ensure pathogen clearance. To do so, immune cells activate several important 
metabolic pathways to meet their demands. 
 
1.2.1 Activation of T lymphocytes 
 
To proliferate and differentiate, T cells rely on antigen recognition, co-stimulation and 
cytokines. Antigen recognition is the first step of activation ensuring a specific 
immune response. Therefore, the presentation of foreign proteins by major 
histocompatibility antigens (MHC) is mandatory and two different complexes, MHC I 
and MHC II, recruit specific subpopulation of T cells. Upon recognition of unspecific 
microbial patterns, dendritic cells (DCs) or macrophages in the periphery take up and 
process foreign extracellular antigens (for example bacteria or fungi). After 
degradation, antigen fragments consisting of up to 25 amino acids (AA) are 
presented by the major histocompatibility complex II (MHC II), which is only 
expressed on professional antigen presenting cells (APCs) like DCs or macrophages. 
The activated APCs thereupon migrate to secondary lymphoid tissues such as lymph 
nodes or the spleen, where circulating naïve CD4+ lymphocytes (= T helper cells, Th 
cells) expressing CD4-assosciated T cell receptors (TCRs) are stimulated. In 
contrast, CD8+ T cells (= cytotoxic T cells, CTLs) are activated by the major 
histocompatibility complex I (MHC I) expressed by every nucleated human cell. In the 
course of the turnover of cellular proteins, short amino acid chains (< 10 AA) are 
connected with the histocompatibility complex and presented at the cell surface. 
Virus- or tumor-caused alterations in those patterns are detected by specific, CD8-
associated TCRs and result in an activation of the CTL. Similar to CD4+ T cells, 
activation of CD8+ T cells can be also initiated by antigen presenting cells, which 
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requires a pathway called “cross-presentation”: for reasons, which have not yet been 
entirely explained, APCs are able to ingest infected cells or secreted tumor- or virus-
proteins and load to MHC I instead of MHC II. Furthermore, cytokines produced by 
CD4+ T cells also recognizing the respective pathogen (see below) are able to 
enhance or even initiate the differentiation of CTLs. It is assumed, that especially 
CTLs coping with latent viral infections or tumors eliciting a limited innate immune 
response depend on the interaction with both, APCs and CD4+ helper cells (81).      
The T cell receptor complex consists of (i) the receptor part with two highly varying, 
via disulfide bonds connected chains (α- and β-chain) recognizing the cell-specific, 
MHC-bound antigen, and (ii) the non-covalently associated CD3- and ζ-proteins, 
which transduce the stimulation signal. The CD4- respectively CD8-molecules are 
transmembrane glycoproteins of the Ig superfamily, which bind to non-polymorphic 
sections of the MHC and are responsible for the MHC-restriction of the particular cell 
(CD4 to MHC II, CD8 to MHC I). Intracellular kinases connected to these molecules 
enable the signal transduction by phosphorylation of CD3- and ζ-proteins (81).  
Besides the TCR stimulation, further co-stimuli are necessary to fully activate T cells. 
These additional signals are cell-to-cell- or cytokine transmitted and depend on a 
prior APC stimulation. The TCR stimulation without co-stimulation results in anergy, 
describing a cellular hyporesponsiveness to a further T cell receptor stimulation.  
Binding of CD28, expressed on the surface of T cells, by the APC ligands B7-1 and 
B7-2 (= CD80 and CD86) amplifies or even initiates the signal transduction especially 
via the activation of the PI3K/Akt pathway (96). Its importance is underlined by the 
fact, that knock-out of or mutations in genes encoding these proteins result in severe 
immune deficiency (17, 81). While about 80 % of CD4+ T cells express CD28, only 
about 50 % of CD8+ T cells express this co-stimulatory ligand (97). Also the CD40 
ligand (CD40L), a tumor necrosis factor superfamily membrane protein on the helper 
T cell surface, binding the receptor CD40 on the APC surface leads to an increased 
B7-1/B7-2 expression and cytokine production thus providing a positive feedback 
loop. This process called licensing additionally enhances CTL differentiation (81).  
Besides the membrane bound co-stimulatory molecules also humoral factors support 
and enhance the activation of lymphocytes. The most important cytokine for T cell 
stimulation is IL-2, which is early produced by innate immune cells and later 
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synthesized and secreted by CD4+ T helper cells, acting in an auto- as well as 
paracrine manner. The secretion peak is reached 8-12 hours upon antigen 
recognition and IL-2 interacts with the type I cytokine receptors. IL-2 binding to the IL-
2 receptor α (IL2-Rα, CD25) supports cell cycle progression and proliferation, survival 
and secretion of effector proteins such as IFNɣ (81, 92). Other cytokines playing a 
crucial role in T cell stimulation are IL-12, IL-15 and IL-21.  
Upon ligation of the TCR and co-stimulation, the PI3K pathway is activated. The 
consecutive activation of the downstream kinase Akt contributes to cell survival by 
inhibition of members of the Bcl-2 family. Also the MAP (mitogen-activated protein) 
kinase cascade, involving Ras/Raf/MEK/ERK, is initiated and results in the synthesis 
and activation of the transcription factor activator protein 1 (AP-1). The TCR-
dependent activation of the enzyme phospholipase C ɣ1 (PLCɣ1) catalyzes the 
reaction of the membrane-bound phosphatidylinositol-4,5-bisphosphate (PIP2) into 
the soluble inositol-1,4,5-triphosphate (IP3) and diacyl glycerol (DAG). IP3 leads to 
an increase of cytosolic calcium and via calmodulin and calcineurin to the activation 
of the transcription factor nuclear factor of activated T cells (NFAT), whereas DAG 
recruits the protein kinase C (PKC) and therewith activates the nuclear factor κB 
(NFκB). These transcription factors are responsible for the expression of anti-
apoptotic proteins, enhanced proliferation, increased cytokine production as well as 
differentiation of naive T cells into effector and memory cells  (81). 
Besides activating co-receptors also inhibiting counterparts (= immune checkpoints) 
play a crucial role in balancing the immune response avoiding both 
immunodeficiency and autoimmune reactions. B7-1 and B7-2, ligands on the surface 
of APCs, are bound by the membranous T cell molecule cytotoxic T lymphocyte 
antigen 4 (CTLA-4, CD154), which is also engaged upon activation and shows a 
considerably higher affinity to B7 compared to the CD28 receptor. Especially when 
B7 levels are low, this connection leads to a negative regulation of the immune 
response and self-tolerance. A similar effect is achieved by the connection of the 
programmed death ligand 1 (PD-L1) on APCs to its receptor programmed death 1 
(PD-1) on T cells. These mechanisms mediate the inactivation of the immune system 
to prevent systemic damage by overstimulation or the development of autoimmune 
reactive T cell clones by MHC-presentation of autologous peptides without 
expression of co-stimuli (81). 
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1.2.2 Effector functions of activated T cells 
 
T cells are responsible for the cell-mediated part of the adaptive immune response. 
CD8+ T cells directly eliminate infected and transformed cells by apoptosis inducing 
ligands and cytotoxic proteins. In contrast, CD4+ T cell subpopulations attract, control 
and activate innate immune cells like macrophages and neutrophils by cytokine 
secretion and surface molecule expression. Depending on the particular T cell 
subtype different leukocytes are recruited. Additionally, CD4+ T cells can acquire a 
cytotoxic phenotype contributing to lysis of malignant or infected host cells (98, 99). 
CD8+ T cells (CTLs) directly attack every kind of cell harboring intracellular microbes, 
but also neoplastic cells. Following differentiation and activation in secondary 
lymphoid organs, CTLs enter infection sites and bind to target cells presenting 
specific virus- or tumor-altered cellular proteins by class I MHC. After binding to the 
MHC I, the immunologic synapse is formed by the adhesion molecules intercellular 
adhesion molecule 1 (ICAM-1) and lymphocyte function-associated antigen 1 (LFA-
1). This close connection prevents damage of healthy neighboring cells. CTLs secret 
perforin and granzymes, which perforate the target cell membrane and induce 
apoptosis. Furthermore, CTLs express the membrane protein Fas ligand (FasL, 
CD95), which binds the ubiquitously expressed death receptor Fas and also 
mediates cell death via caspase activation (81).  
To avoid recognition and elimination, tumor cells engage many mechanisms. As T 
cell activation relies on the MHC presentation, many tumors show downregulated 
MHC I expression to get “invisible” to CTLs. Another strategy is the suppression of T 
cell activation by upregulated PD-L1 expression. Furthermore, tumor antigens can be 
presented on MHC II but with low B7 levels on the APCs. This combination supports 
the CTLA-4- instead of the CD28-binding by B7 family members also inhibiting T cell 
activation. Additionally, tumor produced humoral factors such as transforming growth 
factor β (TGFβ) prevent T cell proliferation and effector functions (81).  
Activated CD4+ T cells differentiate in a variety of subpopulations: Th1, Th2 and Th17 
cells, displaying different functions.  
Th1 cells are mainly activated by APCs secreting IL-12 upon pathogen recognition. 
The Th1 subpopulation is characterized by production and secretion of IFNɣ 
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supporting macrophage activation and the killing of phagocytosed microbes by 
reactive oxygen species (ROS) and lysosomal enzymes. Beyond that IFNɣ-activated 
macrophages secret chemokines to recruit innate immune cells and produce IL-12 to 
amplify the Th1 response. An IFN-mediated antibody switch of IgG to subclasses 
promoting opsonization and phagocytosis of extracellular microbes supports this 
mechanism. Additionally, IFNɣ increases the MHC expression and MHC-mediated 
pathogen presentation leading to a stronger activation thereby resulting in a positive 
feedback loop.  
Th2 cells in contrast are primarily stimulated by allergens and chronic inflammations 
without innate immune cells. These cells coordinate an immune response performed 
by mast cells, basophils and eosinophils via secretion of IL-4, IL-5 and IL-13. 
Thereby, IL-4 and IL-13 regulate the antibody switch to IgE, whereas IL-5 stimulates 
eosinophils. Further on, especially IL-13 increases the mucosal barrier function by 
stimulation of mucus production.  
Immune response mediated by Th17 cells is stimulated by extracellular fungi and 
bacteria, which are recognized and presented via the MHC II by APCs. IL-17 
produced by Th17 cells activates neutrophils and monocytes.  
CD4+ T helper cells enhance the antitumor response by production of cytokines 
which are necessary for the differentiation of CD8+ effector cells. Additionally, 
secretion of IFNɣ and TNFα increases MHC I expression in target cells thus 
supporting recognition by CTLs (81). 
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1.2.3 Metabolism of T lymphocytes 
1.2.3.1 Metabolism of quiescent T cells 
 
As shown in figure 3, quiescent cells cover their energy demand utilizing glucose and 
fatty acids to generate ATP by oxidative phosphorylation (OXPHOS) (100, 101). This 
metabolic phenotype is not static, but relies on different growth signals to prevent 
apoptosis and maintain intracellular glucose concentrations. A permanent, weak T 
cell receptor (TCR) signal is necessary to maintain a critical amount of GLUT1 on the 
surface and oxidative energy production by stimulation of mitogen-activated protein 
kinase (MAPK) and AMP-kinase (AMPK) pathways (92).  
Besides the TCR signals also interleukin 7 (IL-7) prevents cell death via stabilizing 
the balance between pro- (Bim) and anti-apoptotic members (Bcl-2 and Mcl-1) of the 
B cell lymphoma 2 family (102) by binding to the IL-7 receptor (IL-7R). This 
homeostasis is a critical process to avoid both, immunodeficiency by lacking of 
adequate cell numbers and autoimmune diseases by uncontrolled proliferation. 
Additionally, also IL-7 promotes the glucose metabolism and glycolysis by expression 
and the surface trafficking of GLUT1 and therewith increased glucose uptake via the 
activation of the januskinase (Jak)/signal transducer and activator of transcription 5 
(STAT5) and the PI3K/Akt pathway. In contrast to activated T cells, quiescent cells 
show a delayed, but at low levels constant Akt activation (103). 
 
1.2.3.2 Metabolism and function of activated T cells 
 
Upon activation murine T cells immediately increase the expression of various 
surface molecules as well as the secretion of cytokines, followed by a massive clonal 
expansion. For this reason, stimulated T cells have a high demand for biomolecules 
(DNA, lipids, amino acids) required for cell growth, proliferation and production of 
effector proteins. To meet this demand increased metabolic activity is necessary 
(104) and T cell metabolism shifts, as shown in figure 3 (101), from OXPHOS to 
glycolysis to support the highly proliferative phenotype (105). Binding of the TCR 
complex and co-stimulatory receptors results in increased PI3K/AKT/mTORC1, 
AMPK and MAP kinase activity, regulating transcription factors such as c-Myc or 
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NFAT (106, 107). Glycolysis, glutaminolysis and mitochondrial activity are 
upregulated by expression of rate-limiting enzymes and the surface trafficking of 
appropriate transporters (96, 108, 109). The metabolic profile of activated T cells 
closely resembles the profile observed in tumor cells. 
Frauwirth et al. demonstrated, that CD28 co-stimulation is crucial for the 
enhancement of glucose metabolism in T cells by upregulation of the PI3K/Akt 
pathway (96). This results in increased GLUT1 and GLUT3 levels to foster glucose 
up-take required for the replenishment of intracellular building blocks (110) as well as 
elevated activity of glycolytic enzymes e.g. HK and PKM2 (101). Neither TCR/CD3 
stimulation alone nor IL-2 binding to IL-2 receptors are able to induce and maintain a 
comparable metabolic state in T cells (96). Interestingly, the CD28 ligation alone 
does not induce glucose metabolism and stimulation of further, TCR-associated 
pathways, such as the MAP kinase cascade, is required. Especially ERK is 
necessary to increase the hexokinase activity (111). Furthermore, it is well-known, 
that some of the glycolytic enzymes are able to affect genetic transcription or 
stabilize transcriptional factors, respectively, representing a linkage between the T 
cell effector function and metabolism (112). Similar to tumor cells, glucose serves as 
a carbon source for nucleotides and NADPH redox equivalents via the pentose 
phosphate pathway as well as amino acid synthesis. Provision of these building 
blocks is necessary for the proliferation (111, 113) and inhibition of glycolysis by 2DG 
results in a significant proliferation arrest of murine T cells (107, 114, 115). 
Furthermore, in the murine system a strong link between the production of the 
effector cytokine interferon ɣ and glycolysis is reported (113, 116, 117). Glucose 
regulates the dissociation of the enzyme glyceraldehyde-3-phophate dehydrogenase 
(GAPDH) from the  3´ UTR (= three prime untranslated region) of IFNɣ, which 
enables the translation of IFNɣ (118). Accordingly, it is shown that 2DG inhibits the 
IFNɣ production (119). Cham and Gajewski demonstrated that 2DG also reduces IL-
2 production in murine T cells (120). On the other hand it has been shown that 
glucose starvation affects whether IL-2 production by murine CD4+ cells nor cytotoxic 
activity of murine CD8+ T cells (113, 121). 
Upregulated glutamine uptake replenishes the TCA cycle, supports maintenance of 
mitochondrial membrane potential and acts as a biomolecular precursor of lipids and 
amino acids (92, 104, 122–125). Inhibition of glutaminolysis is shown to impede 
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murine T cell growth and proliferation (126), whereas IFNɣ and IL-2 are produced in 
glutamine free environment. However, presence of glutamine results in a further 
stimulation (127, 128).   
Studies analyzing the importance of mitochondrial energy production for proliferation 
and effector functions of activated T cells are contradictory. Mitochondrial ATP 
seems to be important for proliferation and memory T cell development (118). Also, 
IL-2 production depends on OXPHOS and reactive oxygen species (ROS) generation 
(129). However, the inhibition of mitochondrial respiration has no impact on the IFNɣ 
production in murine CD4+ T cells (118), whereas the blockade in murine CD8+ T 
cells is shown to distinctly reduce interferon secretion (130).  
The link between metabolism and function of human T lymphocytes is much less 
elucidated, but numerous aspects show significant differences between the murine 
and the human immune system (131). For example, glucose restriction results in 
severely impaired proliferation but preserved IFNɣ production in human T cells, 
whereas murine T cells cannot maintain interferon secretion. Glycolytic inhibition by 
2DG in contrast affects effector functions (132). Upon activation, increased glucose 
and glutamine uptake are linked to proliferation and cytokine production (96, 108, 
133). However, human memory CD8+ T cells rely on an early glycolytic switch to 
ensure a sufficient IFNɣ production (114), whereas human CD4+ T cells maintain 
their functions even under conditions of energy restriction (134). Taken together, the 
link between metabolism and effector functions is still not clear. 
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Figure 3. Metabolic re-programming during T cell activation 
(a) Naïve T cells surveil secondary lymphoid tissues. Therefore necessary energy is mainly produced by OXPHOS 
and fatty acid oxidation (FAO). Low levels of IL-7 binding to IL-7 receptor (IL-7R) ensure adequate amounts of 
surface glucose transporters via PI3K/Akt/mTOR pathway. (b) Upon activation T cells undergo a massive clonal 
expansion. TCR/CD28-mediated pathways inhibit FAO and OXPHOS, while upregulated glucose transporters and 
glycolytic enzymes maintain high levels of important building blocks (modified after Herbel et al., Clinical and 
translational medicine, 2016, reprint permitted by the authors (101)) 
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2. Research objectives 
 
One of the main aspects of nowadays cancer research is the development of 
targeted therapies to reduce treatment related adverse side effects and increase 
therapeutic efficacy. Therefore, characteristics distinguishing tumor cells from non-
malignant cells are under investigation. In this context also the altered tumor cell 
metabolism is under consideration. Most solid tumors but also leukemic cells are 
characterized by an upregulation of glucose metabolism. Its inhibition is shown to 
effectively impair tumor growth and viability. Moreover, anti-glycolytic treatment 
reduces the secretion of the immunosuppressive metabolite lactic acid. Taken 
together, glucose metabolism represents a promising therapeutic target.  
However, it has been shown, that murine primary T cells also rely on glucose 
metabolism to sustain proliferation and effector functions. In line, glycolytic inhibition 
impairs proliferation and secretion of key cytokines such as IFNɣ. As the number and 
activity of tumor infiltrating T cells positively correlate with patient prognosis, anti-
glycolytic treatment might severely affect patient outcome.  
The aim of this study was the development of an anti-glycolytic treatment, effectively 
targeting tumor glucose metabolism, but preserving effector functions of human T 
cells. Data on the link between metabolism and human T cell function are rather 
sparse. In this study, therefore, glucose metabolism was analyzed in relation to 
function of stimulated human CD4+ and CD8+ T cells. In addition, the impact of two 
glycolytic inhibitors, 2DG and diclofenac, on proliferation and viability of malignant T 
lymphocytes was investigated in comparison to primary CD4+ and CD8+ T cells. 
Finally, effects of glycolytic inhibitors on effector functions such as IFNɣ production of 
human T cell populations were examined.  
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3. Material and methods 
3.1 Material 
3.1.1 Devices 
 
Advia 1650  Bayer HealthCare, Tarrytown (NY, USA) 
CASY cell counter Roche Innovartis, Bielefeld 
EMax Precision microplate reader Molecular Devices, Sunnyvale (CA, 
USA) 
FACS Calibur BD Bioscience, Heidelberg 
Incubator (BBD 6220) Heraeus, Osterode 
Multifuge 3S-R Thermo Scientific, Waltham 
Multifuge 3.0R Thermo Scientific, Waltham 
Sepatech Megafuge 1.0 Heraeus, Osterode 
Sepatech Megafuge 3.0 cooling 
centrifuge 
Heraeus, Osterode 
Thermo VarioSkan Thermo Scientific, Waltham 
Vortex Genie 2 Scientific Industries, Bohemia (NY, USA)  
  
3.1.2 Pipettes, plates, flasks, tubes 
 
Research Plus (pipettes),  
10/100/1000 µl 
Eppendorf AG, Hamburg 
Serological Pipettes,  
1/2/5/25 ml 
Nerbe plus, Winsen  
Pipetboy acu Integra Bioscience, Zizers (CH) 
Polystyrene Round-Bottom Tubes 5 ml 
(FACS tubes) 
Corning Science, Tamaulipas (Mexico) 
Tube Racks 15/50 ml Greiner Bio-One, Kremsmünster (AUT)  
96 well plates U-/flat-bottom Costar, Corning 
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3.1.3 Medium, buffers, solutions 
 
Annexin binding buffer BD, Franklin Lakes (NJ, USA) 
Aqua Ecotainer B. Braun, Melsungen 
FACSclean BD, Franklin Lakes (NJ, USA) 
FACSflow BD, Franklin Lakes (NJ, USA) 
FACSrinse BD, Franklin Lakes (NJ, USA) 
Lymphocyte separation solution (Ficoll)  PAA, Linz (AUT) 
Phosphate buffered saline (PBS) Biochrome, Berlin 
Dulbecco´s PBS without Ca2+/Mg2+ PAA 
 
T cell medium  
500 ml RPMI 1640 PAN Biotech, Aidenbach 
5 ml instable L-glutamine Biochrome, Berlin 
5 ml Nonessential amino acids Gibco 
5 ml Sodium pyruvate Gibco 
0.5 ml β-mercaptoethanol Gibco 
2.5 ml Penicillin/Streptomycin 
(10.000U/ml) 
Gibco 
10 % AB-Serum, human PAN Biotech, Aidenbach 
 
Tumor cell (C7H2) medium 
500 ml RPMI 1640  PAN Biotech, Aidenbach 
2 ml instable L-glutamine Biochrome, Berlin 
10 % FCS Gibco 
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DC medium 
500 ml RPMI 1640 PAN Biotech, Aidenbach 
1.0 %  instable L-glutamine Biochrome, Berlin 
2.5 ml Penicillin/Streptomycin 
(10.000U/ml) 
Gibco 
10 % FCS (fetal calf serum) Gibco 
 
FACS staining buffer 
PBS + 2 % AB-serum 
 
MACS buffer 
PBS + 2 mM EDTA + 1 % FCS  
 
3.1.4 Cell separation 
 
QuadroMACS® separator Miltenyi Biotec, Bergisch Gladbach 
LS Columns  Miltenyi Biotec, Bergisch Gladbach 
CD4 MicroBeads, human Miltenyi Biotec, Bergisch Gladbach 
CD8 MicroBeads, human Miltenyi Biotec, Bergisch Gladbach 
 
3.1.5 Apoptosis staining 
 
Dye Company Vol./test 
Material 
number 
FITC Annexin V BD 5 µl 556419 
7-AAD BD 20 µl 559925 
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3.1.6 Antibodies and isotypes 
 
3.1.7 Kits, cytokines 
 
Dynabeads® Human T-Activator 
CD3/CD28 
Gibco/Invitrogen  
Human IFN gamma DuoSet ELISA R&D Systems, Wiesbaden 
Human IL-2 DuoSet ELISA R&D Systems 
Human IL-10 DuoSet ELISA R&D Systems 
Glucose (HK) Assay Kit Sigma, St. Louis (USA) 
IL-2 PeproTech, Hamburg 
 
 
 
 
 
 
Anti-human 
antibody 
Conjugate Company Clone 
Isotype 
(Mouse) 
Vol./test 
Material 
number 
CD4 PE BD RPA-T4 IgG1, к 5 µl 561844 
CD8 PE-Cy7 BioLegend SK1 IgG1, к 10 µl 344711 
CD25 PE-Cy7 BD M-A251 IgG1, к 5 µl 557741 
CD95 FITC BD DX2 IgG1, к 20 µl 561975 
CD137 PE eBioscience 4B4 IgG1, к 5 µl 12-1379 
Isotype 
(Mouse) 
Conjugate Company Clone Vol./test 
Material 
number 
IgG1, к FITC BD MOPC-21 20 µl 555909 
 PE-Cy7 BioLegend MOPC-21 20 µl 400126 
 PE BD MOPC-21 20 µl 555749 
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3.2 Methods 
3.2.1 Tumor cell line cultivation 
 
As representative of a malignant T-ALL cell line CEM-CCRF-C7H2 cells, first isolated 
by Norman and Thompson in 1977 (135), was used. These cells were cultivated in 
tumor cell medium at a starting concentration of 300.000 cells per ml in a total 
volume of 20 ml. Incubation was performed in a humidified atmosphere (5 % CO2, 95 
% air) at 37° Celsius and cells were split every second day. 
 
3.2.2 T cell isolation, stimulation and cultivation 
 
Human peripheral blood mononuclear cells (PBMCs) were separated from blood of 
healthy donors by leukapheresis via a density gradient centrifugation (2000 rpm, 25 
min, room temperature) over Ficoll/Hypaqua and subsequent countercurrent 
centrifugation (elutriation). Cells were collected from the interphase and washed with 
PBS (two times 1800 rpm, 7 min, 4°C, third time 1200 rpm, 7 min, 4°C). The study 
was approved by the local ethical committee and all human participants gave written 
informed consent.  
CD4+ and CD8+ T cells were isolated by magnetic separation. Therefore, 108 
monocyte-depleted PBMCs were solved in 160 µl MACS buffer and incubated with 
40 µl magnetic anti-CD4 or anti-CD8 MicroBeads. After incubation, cells were 
washed with MACS buffer, centrifuged and resuspended. The cell suspension was 
applied on LS columns and magnetically separated by a MACS separator. After 
separation, purity of populations was determined by anti-CD4 and anti-CD8 staining 
and analyzed by flow cytometry. Thereby a purity of more than 98 % was achieved 
(figure 4). 
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Subsequently, cells were solved in T cell medium supplemented with IL-2 (100 IU/ml) 
and plated on 96 well plates together with anti-CD3/CD28 beads in a ratio of 1:1 (105 
cells, 105 beads, total volume 225 µl). As a control T cells were plated without anti-
CD3/CD28 beads under identical conditions (= quiescent T cells). Plated T cells were 
cultured in a humidified atmosphere (5 % CO2, 95 % air) at 37° Celsius. In figure 5 a 
detailed experimental time course is presented. 
Figure 4. Purity of freshly isolated example donor CD4
+
 and CD8
+
 T cells 
Subpopulations were stained with anti-CD4
+
 and anti-CD8
+
 antibodies immediately after magnetic bead 
separation and analyzed by flow cytometry. 
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Figure 5. Schedule of T cell cultivation and time points of measurements 
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3.2.3 Mixed leukocyte reaction (MLR) 
 
T cells were stimulated in a mixed leukocyte reaction (MLR), representing a more 
physiological stimulus. In a MLR T cells are activated by allogenic antigen presenting 
dendritic cells (DCs). Monocytes were differentiated to dendritic cells by stimulation 
of 1.5 x 106 cells per ml with IL-4 (144 U/ml), colony stimulating factor GM-CSF (224 
U/ml) and after 4 days matured with lipopolysaccharide LPS (100 ng/ml) in DC 
medium for two days. Matured DCs were centrifuged (1600 rpm, 4 min, 4 °C) and re-
suspended in T cell medium. DCs were plated on 96 well plates with freshly isolated 
T cells at a ratio of 1:10 (10.000 DCs, 100.000 T cells) in a total volume of 225 µl T 
cell medium supplemented with IL-2 (100 IU/ml). A medium exchange (150 µl of 
initial 225 µl) was performed on day four and T cells were harvested after seven days 
of stimulation.  
 
3.2.4 Determination of cell number and cell size 
 
Measurement of proliferation and cell growth was performed with the CASY system. 
Cells were pooled and separated from anti-CD3/CD28 beads by magnetic 
separation. 50 µl of the cell suspension were mixed with 10 ml of CASY buffer. 
Principle of the CASY technology is the electric acquisition of cells passing through a 
measurement pore. The resulting signal depends on the cell volume (electrical 
current exclusion, ECE), which leads to detection of cell size and number.    
 
3.2.5 Measurement of glucose consumption and lactate secretion 
 
After magnetic separation from anti-CD3/CD28 beads and pooling, cell suspension 
was centrifuged (1600 rpm, 4 min, 4°C) and supernatant was drawn and stored at -
20 °C for determination of glucose and lactate concentrations. Glucose consumption 
and lactate secretion were calculated as the difference between the concentration in 
the standard medium and culture supernatant. 
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Glucose was measured by an enzymatic assay. In a first reaction, glucose was 
converted into glucose-6-phosphate (G6P) by the enzyme hexokinase degrading 
ATP. In a second step, G6P and NAD were converted to 6-phosphogluconate and 
NADH by glucose-6-phosphate dehydrogenase (G6PDH). NADH was measured at 
340 nm by a spectrophotometer (Thermo VarioSkan plate reader). Glucose level was 
calculated by a linear standard curve (measurement of a serial diluted standard 
sample).  
Lactate was also determined enzymatically by means of an ADVIA 1650 analyzer 
using reagents from Roche at the Department of Clinical Chemistry (University 
Hospital of Regensburg). Therefore, 250 µl of sample was diluted with 250 µl PBS 
and measured. 
 
3.2.6 Determination of cytokines 
 
Measurement of the cytokines IFNɣ, IL-2 and IL-10 was performed by using ELISA-
kits (enzyme linked immunosorbent assay) in culture supernatants after 
centrifugation (1600 rpm, 4 min, 4°C). In brief, the principle of this measuring method 
is a multistep reaction, with initial binding of a cytokine specific capture antibody to a 
microplate. In the next step, standard or samples are added, followed by a detection 
antibody. Subsequently, this antibody binds Streptavidin-Horseradish peroxidase 
(HRP), which then converts the finally added blue substrate tetramethylbenzidine 
(TMB) to a yellow dye with intensity depending on the substrate concentration. This 
color change is measured by a microplate reader set to 450 nm with wavelength 
correction set to 540 nm. The achieved row data are converted to cytokine 
concentrations by using a standard curve. The measurements were performed 
according to the manufacturer´s protocol. 
 
3.2.7 Flow cytometry 
 
Cells solved in FACS buffer were aspirated and excited by a laser beam. Deflection 
of the laser light causes a light scatter depending on cell size (“forward scatter”) and 
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intracellular granularity (“sideward scatter”). Staining with fluorescent dyes 
conjugated to antibodies enables determination of intracellular and surface proteins. 
In this work, flow cytometry was used to measure viability and expression of the 
surface markers CD4, CD8, CD25, CD95 and CD137. 
 
Viability was determined by FITC labeled Annexin V and 7-amino-actinomycin D (7-
AAD) staining. Annexin V binds to phosphatidylserine, which is switched to the 
outside of the plasma membrane in apoptotic cells. 7-AAD interacts specifically with 
cytosine and guanine of cellular DNA, which is only possible in late apoptotic cells 
with a disrupted plasma membrane. Cells were harvested, pooled and separated 
from beads at different time points (Fig. 5). 0.25 x 106 cells were centrifuged (1600 
rpm, 4 min, 4°C), washed two times with 1 ml PBS, supernatant was discarded and 
cells were stained. Subsequently, cells were re-suspended in 400 µl Annexin binding 
buffer diluted 1:10, stained with 5 µl Annexin V FITC and 20 µl 7-AAD and incubated 
for 20 minutes in the dark. Unstained and single-stained (Annexin V FITC or 7-AAD) 
cells were used to compensate and calibrate measurement settings. Measurements 
were performed with FACS Calibur, analyzation of data with the Cell Quest software. 
Double negative cells (Annexin V/7-AAD -/-) were defined as viable cells. 
 
Expression of surface markers was measured by antibody staining. Antibodies 
applied were anti-CD4/CD8 (purity control upon isolation), anit-CD137 (early 
activation marker) and anti-CD25/CD95 (activation markers) at different time points 
(figure 5). Cells were separated from the magnetic beads, centrifuged (1600 rpm, 4 
min, 4°C), supernatant was discarded and cells were washed two times with 1 ml 
FACS buffer. Cells were stained with 5 µl anti-CD4, 10 µl anti-CD8, 5 µl anti-CD25, 
20 µl anti-CD95 or 5 µl anti-CD137. After an incubation period (20 min, 4°C), cells 
were washed again two times with 1 ml FACS washing buffer and finally re-
suspended in 400 µl FACS buffer and measured. Quiescent, stained cells 
respectively isotype stained activated T cells were used as controls for unspecific 
antibody staining.  
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3.2.8 Restriction of glycolysis 
 
To inhibit glucose metabolism, two different agents were used: the hexokinase 
inhibitor 2-deoxyglucose (2DG) and the non-steroidal anti-inflammatory drug (NSAID) 
diclofenac (diclo). 2DG was solved in standard medium to a stock concentration of 
200 mmol/l (200 mM) and applied in concentrations of 1 mM, 5 mM and 10 mM. 
Diclofenac was solved in standard medium to a stock concentration of 8 mM and 
applied in concentrations of 0.1, 0.2 and 0.4 mM. 
 
3.3 Statistics 
 
Statistics were performed by use of the software “GraphPad Prism 5” and depicted 
graphs show means with standard error of the mean (SEM). When comparing two 
groups, significance levels were calculated by the paired and two-tailed Student´s t 
test. In contrast, treatment induced changes were analyzed by ANOVA and post-hoc 
Tukey´s multiple comparison test. P values of < 0.05 were considered as statistically 
significant (*), < 0.01 as being very significant (**) and < 0.001 as highly significant 
(***). 
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4. Results 
4.1 Impact of glycolytic inhibition on leukemic T-ALL cells 
 
In a first step the impact of targeting glucose metabolism on human leukemic cells 
was investigated. The human childhood T-ALL cell line CCRF-CEM-C7H2 (C7H2) 
was used as a model system for leukemia. We compared the impact of diclofenac, 
recently described as a glycolytic inhibitor, with 2DG, a well-established glycolytic 
inhibitor. Diclofenac was applied in concentrations of 0.1 mM, 0.2 mM and 0.4 mM 
and 2DG in concentrations of 1 mM, 5 mM and 10 mM. 
 
4.1.1 Impact on glucose consumption and lactate production 
 
As shown in figure 6A the untreated cultures metabolized 85 % of medium glucose 
within 72 hours of cultivation. 2DG and diclofenac treated cells showed a significant 
reduction of glucose consumption in a concentration dependent manner. Similar 
levels of glycolytic inhibition were obtained with applied concentrations of both 
inhibitors. A 2DG concentration of 1 mM decreased glucose consumption by about 
30 %, application of 5 and 10 mM resulted in an almost complete inhibition (fig. 6A). 
0.1 mM diclofenac diminished glucose consumption by more than 60 % and the two-
fold concentration resulted in an almost complete blockade (fig. 6A).  
The increased glucose metabolism resulted in a highly elevated lactate production 
and secretion in C7H2 cell cultures (fig. 6B). Treatment with the two different 
inhibitors diminished lactate secretion in a concentration dependent manner. Lactate 
production was reduced significantly by all treatments and especially high doses (0.2 
mM diclofenac and 10 mM 2DG) achieved a reduction by about 90 %.  
Glycolytic activity was compromised more effectively by 0.1 mM diclofenac compared 
to 1 mM 2DG treatment, whereas 0.2 mM diclofenac showed comparable effects to 5 
and 10 mM 2DG.   
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4.1.2 Impact on proliferation and viability 
  
Glucose metabolism is pivotal for the proliferation of cells. Therefore, cell division 
was analyzed under 2DG and diclofenac treatment. 
Both inhibitors led to a reduction in proliferation. Low doses of 1 mM 2DG and 0.1 
mM diclofenac slightly diminished cell number by about 20 %, whereas higher 
concentrations of both inhibitors severely and comparably suppressed cell division 
(fig. 7A).     
Untreated controls of C7H2 cells showed an overall survival of 92 % over the entire 
incubation time (fig. 7B). As already mentioned, the metabolism of malignant cells is 
characterized by a shift to glycolysis, which allows the presumption of an important 
and particular role of glucose metabolism. Therefore, the impact of glycolytic 
inhibition on the viability of C7H2 cells was analyzed.  
Interestingly, 2DG had only little impact on tumor cell viability. Even 10 mM 2DG, 
which is clinically not applicable, reduced cell viability only by 35 %. Despite 
comparable effects on glucose metabolism and proliferation, diclofenac exerted a 
stronger impact and reduced cell viability very effectively. Within 72 hours 0.2 mM 
induced a decline in cell viability by 76 %. 
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Figure 6. Impact of 2-deoxyglucose and diclofenac on glucose metabolism of C7H2 cells 
C7H2 cells were incubated with different concentrations of the glycolytic inhibitors diclofenac (diclo) and 2-
deoxyglucose (2DG) for 72 hours. (A) Glucose and (B) lactate concentrations were measured in the culture 
supernatant. A and B untreated and 0.1 diclo n=9, 0.2 diclo n=8, 2DG n=3 (P value 0.05>*>0.01>**>0.001>***, 
0.05>#>0.01>##>0.001>###, treatment induced changes were analyzed with ANOVA and post-hoc by Tukey´s 
multiple comparison test) 
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Taken together, both glycolytic inhibitors diminished glucose metabolism effectively 
and to a comparable extent. Both inhibitors significantly reduced proliferation, 
however only diclofenac exerted a significant impact on cell viability, pointing towards 
additional effects of diclofenac. 
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Figure 7. Impact of 2-deoxyglucose and diclofenac on cell number and viability of C7H2 cells 
C7H2 cells were incubated with different concentrations of the glycolytic inhibitors diclofenac (diclo) and 2-
deoxyglucose (2DG) for 72 hours. (A) Cell number was determined with the CASY system and (B) viability by flow 
cytometry using Annexin V and 7-AAD staining. A untreated and diclo n=5, 2DG n=3; B untreated and 0.1 diclo 
n=11, 0.2 diclo n=9, 2DG n=3. (P value 0.05>*>0.01>**>0.001>***, 0.05>#>0.01>##>0.001>###, treatment 
induced changes were analyzed with ANOVA and post-hoc by Tukey´s multiple comparison test) 
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4.2 Characterization of primary human T cells 
 
Activated murine T cells have a similar metabolic phenotype compared to tumor cells 
in terms of aerobic glycolysis, thereby also reflecting the Warburg effect.  Due to the 
fact that most of the studies were performed in the murine system so far, we 
characterized the kinetics of glucose metabolism in correlation to cell proliferation 
and growth, as well as interferon ɣ production and viability in human bulk CD4+ and 
CD8+ T cells. T cells, purified from healthy donors were stimulated with anti-
CD3/CD28 beads at a cell to bead ration of 1:1. After 7 days cells were collected, 
diluted and restimulated (restimulation) for another week followed by a third 
stimulation. During each stimulation period, samples were analyzed after 24, 48, 72 
hours and 7 days. In comparison, quiescent bulk T cells were analyzed. 
 
4.2.1 Characterization of stimulated human CD4+ T cells 
4.2.1.1 Metabolic characterization 
 
During the first 24 hours of stimulation glucose consumption and lactate production 
were almost below the limit of quantification, but increased after 24 hours and 
strongly accelerated beyond 48 hours (fig. 8A/B). This general pattern was also 
observed during restimulation however restimulated CD4+ T cells showed an 
increased glycolytic activity as reflected by accelerated and significantly elevated 
lactate accumulation. Stimulated and restimulated CD4+ T cells maintained a highly 
glycolytic phenotype up to 7 days (data not shown). A second restimulation did not 
result in any further changes with regard to glucose consumption and lactate 
secretion (n=4, data not shown). 
Quiescent cells kept for 7 days under the same culture conditions were glycolytically 
inactive (n=3, data not shown). 
Interestingly, lactate levels detected exceeded concentrations achievable when 
glucose is completely converted into lactate, strongly indicating that glycolysis is not 
the only source of lactate production. 
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4.2.1.2 Functional characterization 
 
No significant increase in cell number was observed in stimulated and restimulated 
cells during the first 48 hours of culture (fig. 9A) however a strong increase in cell 
size was measured (fig. 9B). The onset of proliferation was detected beyond 48 
hours, concomitantly with a strongly accelerated glucose metabolism. No significant 
differences between stimulation and restimulation were detectable (fig. 9A). Until day 
seven a final cell number of 3.6 * 106 ± 0.20 cells/ml (stimulus, n=10) and 3.16 * 106 ± 
0.49 cells/ml (restimulus, n=6) was achieved. After a second restimulation the 
proliferative capacity within the first 72 hours was reduced (1.13*106 ± 0.09, n=4). 
Unstimulated CD4+ cells showed a minimal proliferation resulting in 0.7 * 106 ± 0.1 
cells/ml within 72 hours (n=3). 
 
The first two days were characterized by a significant cell growth in stimulated cells 
(so-called “on-blast formation”). This initial increase in cell size was followed by a 
slight shrinkage during the proliferative phase until day 7 (data not shown). Another 
significant increase in cell size was detected during the first 48 hours of restimulation, 
however to a much lower extent compared to the first activation (fig. 9B). When 
stimulated a third time, cells showed a slight, but significant cell growth from 9.2 ± 0.1 
µm to 10.7 ± 0.3 µm within 72 hours (n=4). Quiescent T cells did not increase their 
cell size (n=3, data not shown). 
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Figure 8. Metabolic characterization of human stimulated and restimulated CD4+ T cells 
(A) Glucose and (B) lactate levels were measured enzymatically in culture supernatants. A stimulated 24h n=5, 
48h n=7 and 72h n=4, restim n=4, B stim 24h n=5, 48h n=7 and 72h n=8, restim 24h n=5, 48h and 72h n=4. (P 
value 0.05>*>0.01>**>0.001>***, differences between stimulation and restimulation were analyzed with the 
Student´s t-test, paired and two-tailed) 
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Stimulated T cells exhibited a constant viability of 89.7 ± 1.0 % until day 3 (n=4). After 
7 days of cultivation a decline to 71.3 ± 5.4 % (n=4) was observed, which may be 
related to increasing lactate levels in culture supernatants, known to affect T cell 
viability. The loss of viability was reversible and after restimulation cells recovered 
and showed a high viability of 89.7 ± 0.38 % on day 3 (n=4). The same was observed 
during a second restimulation. As expected, unstimulated CD4+ T cells showed a 
slight decline in viability over time from 79.5 % ± 13.7 % after 24 hours (n=3) to 71.2 
% ± 17.3 % after 72 hours (n=3) .  
 
It has been proposed in the murine system, that interferon ɣ production is glucose 
dependent. As shown in figure 9C stimulated cells produced high levels of interferon 
ɣ already in the first 24 hours of stimulation while glucose consumption was very low. 
Interferon ɣ levels remained high up to 72 hours, but concentration dropped to 22.5 ± 
8.3 pg/ml on day seven (n=10). Restimulated cells reached higher IFNɣ 
concentrations compared to stimulated T cells, higher levels were maintained over 
time and even after 7 days significant levels were detectable (253.4 ± 175.0 pg/ml, 
n=5).   
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Figure 9. Functional characterization of human stimulated and restimulated CD4
+
 T cells 
(A) Cell number and (B) mean diameter were determined by CASEY system; (C) Measurement of interferon ɣ 
concentrations was performed by ELISA A and B n=4; C stimulation 24h n=5, 48h n=6 and 72h n=7, 
restimulation 24h n=5, 48h and 72h n=4; (P value 0.05>*>0.01>**>0.001>***, differences between stimulation 
and restimulation were analyzed with the Student´s t-test, paired and two-tailed) 
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4.2.2 Characterization of stimulated human CD8+ T cells 
4.2.2.1 Metabolic characterization 
 
Glucose uptake was below the limit of detection in stimulated CD8+ T cells within the 
first 24 hours (fig. 10A). On day 3 about 50 % of initially available glucose was taken 
up into the cells and the high glycolytic activity persisted over the whole stimulation 
period (data not shown). After restimulation, glucose uptake was significantly 
accelerated in the first 24 hours compared to stimulated cells, however beyond 24 
hours there was no difference detectable between stimulated and restimulated CD8+ 
T cells. During stimulation a slight but significant increase in lactate secretion was 
detected after 24 hours and strongly increased beyond 72 hours (fig. 10B).  
During restimulation significantly elevated lactate secretion was measured only 
during the first 24 hours compared to stimulated CD8+ T cells. A second restimulation 
led to a low glycolytic activity within the first 48 hours and a diminished activity 
beyond 48 hours compared to stimulated and restimulated CD8+ T cells (data not 
shown). After 72 hours only 18 % of glucose was consumed and lactate levels of 9.5 
mM (n=2) were detected. In comparison, stimulated and restimulated CD8+ T cells 
were highly glycolytic beyond 48 hours of stimulation and re-stimulation.  
In quiescent CD8+ T cells lactate levels increased only marginally (data not shown, 
n=2).  
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Figure 10. Metabolic characterization of human stimulated and restimulated CD8
+
 T cells 
(A) Glucose and (B) lactate levels were measured enzymatically in culture supernatants. A stimulation 24h and 
48h n=6, 72h n=4, restimulation 24h n=5, 48h and 72h n=4, B stimulation 24h and 48h n=6, 72h n=4, 
restimulation 24h n=5, 48h and 72h n=4. (P value 0.05>*>0.01>**>0.001>***, differences between stimulation 
and restimulation were analyzed with the Student´s t-test, paired and two-tailed) 
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4.2.2.2 Functional characterization 
 
As shown in figure 11A, cell number increased only slightly within the first two days of 
stimulation. Between day 2 and 3 cell proliferation was significantly accelerated and 
after 7 days a maximum cell number of 2.7 ± 0.37 * 106 cells/ml (stimulation, n=9) 
and 2.4 ± 0.77 * 106 cells/ml (restimulation, n=5) was achieved. During a second 
restimulation cells showed a lower proliferation potential and the average cell number 
after 72 hours amounted to 0.78 * 106 cells/ml (n=2), half of the cell number reached 
during stimulation and restimulation. Within 72 hours, quiescent T cells showed only 
a slight increase in cell number (n=2, data not shown).  
 
Stimulated CD8+ T cells increased their size comparable to CD4+ T cells (fig. 11B), 
whereas restimulated cells grew significantly less within the first 72 hours of 
activation. Between day 3 and 7 a general shrinkage in cell size was observed and 
the final diameter was diminished to 9.1 ± 0.1 µm in stimulated (n=9) and 8.3 ± 0.2 
µm in restimulated (n=5) CD8+ T cells. Equal growth characteristics were observed in 
two-times restimulated CD8+ T cells (data not shown). Quiescent CD8+ T cells 
showed a negligible growth of 11 % within 72 hours (n=2).  
 
Within the first 3 days of stimulation viability remained constant between 80 and 90 % 
(n=4). After a week of stimulation, a significant lower percentage of 72.6 ± 5.2 % 
(n=4) of viable cells was measured, correlating with increasing lactate concentrations 
in culture supernatants, which had been shown to affect cell viability of human T 
cells. Restimulation and associated dilution of cells as well as complete medium 
exchange raised cell viability again to 90.4 ± 1.5 % (n=4) after 72 hours. However 
with increasing proliferation and lactic acid production again a drop to 78.8 ± 1.4 % 
(n=3) was observed between day 3 and 7. Within a second restimulation CD8+ T cell 
viability was constantly compromised and reached a maximum of 72.6 % (n=2) after 
72 hours. Quiescent cells exhibited a decrease in viability within 72 hours from 91.4 
(n=2) to 82.6 (n=2). 
 
Results 
 
42 
 
Already after 24 hours of activation interferon ɣ concentrations of about 500 pg/ml 
were measured (fig. 11C). Concentrations stayed roughly constant until day 3, but 
dropped sharply afterwards concomitant with a strongly accelerated proliferation (on 
day seven 44 ± 15.5 pg/ml, n=7). There was no difference detectable between 
stimulated and restimulated CD8+ T cells. In contrast to CD4+ T cells, interferon ɣ 
levels were not elevated and partially maintained during restimulation. A second 
restimulation resulted in lower concentrations of interferon ɣ with a maximum of 
307.9 pg/ml on day 3 (n=2).  
 
 
 
 
 
 
 
 
 
 
 
4.2.3 Comparison between metabolic activity in CD4+ and CD8+ T cells 
 
Both T cell subpopulations showed an increased glycolytic activity with accelerated 
glucose consumption and lactic acid secretion beyond 48 hours of stimulation and 
restimulation. Thereby, glycolytic activity was higher in CD4+ compared to CD8+ T 
cells. Early glycolytic activity was increased significantly in restimulated T cells 
compared to stimulated T cells. A second restimulation had only little impact on 
glycolytic activity of CD4+ T cells, but glucose consumption and lactate secretion 
were reduced by an average of 25 % in CD8+ T cells within 72 hours. 
Proliferation strongly correlated with glucose metabolism and both subpopulations 
started to proliferate after a 48-hour growth period. Cell size was nearly equal in 
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Figure 11. Functional characterization of human stimulated and restimulated CD8
+
 T cells 
(A) Cell number and (B) mean diameter were determined by CASEY system; (C) Measurement of interferon ɣ 
concentrations were performed by ELISA. A and B n=4; C stimulation 24h and 48h n=6 and 72h n=4, 
restimulation 24h n=5, 48h and 72h n=4; (P value 0.05>*>0.01>**>0.001>***, differences between stimulation 
and restimulation were analyzed with the Student´s t-test, paired and two-tailed) 
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stimulated CD4+ and CD8+ T cells, but while growth was maintained in restimulated 
CD4+ cells, it was significantly diminished in the CD8+ T cells beyond 48 hours. 
Moreover, proliferation was distinctly stronger in restimulated CD4+ compared to 
CD8+ T cells beyond 48 hours. Viability was slightly higher in CD4+ compared to 
CD8+ T cell cultures and both subtypes showed reduced viability upon 24 hours of 
restimulation, which was recovered until day 3 only in CD4+ T cells. 
Interferon ɣ secretion was constant until day 3 in both stimulated cell types, but 
higher in CD8+ than CD4+ T cells. Upon restimulation, IFNɣ secretion was strongly, 
but not significantly increased in CD4+ T cells, whereas CD8+ cells maintained the 
concentration level of first time stimulation. Remarkably, the second restimulation 
resulted in slightly diminished concentrations in both populations, with in average 2.5-
fold higher levels in CD4+ T cells. 
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4.3 Impact of anti-metabolic drugs on human T cells 
 
As shown in the first part malignant T-ALL cells were sensitive to glycolysis inhibiting 
drugs with regard to glucose metabolism, proliferation and viability. The application of 
anti-glycolytic drugs is an emerging strategy in cancer therapy. However, as 
demonstrated in the second part, also human T cells have an increased glucose 
metabolism upon activation. Therefore the question must be asked what 
consequences could arise regarding functionality and efficacy of the anti-tumor 
immune response of T cells in the presence of anti-glycolytic drugs. Therefore, the 
impact of 2DG and diclofenac on human T cell function was analyzed. The 
experimental set-up was equal to the one applied for metabolic characterization of 
quiescent, stimulated and restimulated human T cells.  
 
4.3.1 Impact on quiescent human T cells 
 
In a first step quiescent (i.e. not stimulated) bulk CD4+ and CD8+ T cell cultures were 
treated with 0.1 and 0.2 mM diclofenac. As shown in the first part glucose 
metabolism and proliferation is almost undetectable in unstimulated T cells resulting 
in an limited impact of anti-metabolic drugs. Importantly, viability was preserved (data 
not shown). Because of negligible effects, experiments were performed only two-
times (n = 2).   
 
4.3.2 Impact on stimulated human T cells 
 
As the first stimulation represented an early immune response, the following 
experiments were performed to identify the influence of anti-metabolic drugs on the 
efficacy of primary activation. 
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4.3.2.1 Glucose metabolism 
 
Within the first 3 days of stimulation 2DG was a strong inhibitor of glycolysis and 
already 1 mM 2DG reduced glucose consumption significantly by more than 80 %, 
moreover 5 and 10 mM 2DG led to a complete blockade in uptake (fig. 12A/B). 
Interestingly, after 7 days, the impact of 1 mM 2DG was significantly reduced in both 
populations and glucose uptake was diminished by only 25 %, whereas 5 and 10 mM 
still resulted in a complete block (table 1). 
Already 0.1 mM diclofenac exerted a significant effect on both populations and 
reduced glucose consumption by about 50 % in CD4+ and 60 % in CD8+ T cells 
cultures after 72 hours. 0.2 mM diclofenac diminished glycolytic activity by 75 % 
compared to untreated cells (fig. 12A/B). As observed in 2DG treated T cell 
populations, beyond day 3 a reduced impact on glycolytic inhibition was observed. 
After 7 days, glucose consumption was 80 % under 0.1 mM and 50 % under 0.2 mM 
diclofenac treatment in comparison to untreated cells in both T cell populations (table 
1).  
The reduced glucose metabolism was also reflected in a strongly diminished lactate 
secretion (fig. 12C/D). 1 mM 2DG reduced lactate levels in culture supernatants very 
effectively by about 80 % in CD4+ and CD8+ T cells and the application of 5 and 10 
mM 2DG induced a nearly total block in lactate secretion in the first 72 hours. After 7 
days the reduced impact of 1 mM 2DG on glucose consumption was also observed 
analyzing lactate secretion (only by about 30 % reduced lactic acid) in both 
populations, whereas 5 and 10 mM were still capable to block lactate secretion (table 
1). 
Taken together, inhibition of lactate secretion under diclofenac treatment 
corresponded to glucose consumption in the first 72 hours as well as after 7 days. 1 
mM 2DG and 0.2 mM diclofenac exerted comparable effects on both populations, 
whereas 0.1 mM diclofenac had a significantly lower impact on glycolysis of T cells. 5 
mM and 10 mM 2DG reduced glycolysis significantly stronger than 0.2 mM 
diclofenac. 
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Summarizing, 2DG and diclofenac had a significant impact on aerobic glycolysis 
within 72 hours, which showed a compensation concerning 1 mM 2DG and both 
diclofenac concentrations within 7 days. Despite an exchange of the cell medium 
containing the initial 2DG and diclofenac concentration on day 4, the degradation of 
the active agents within the stimulation period cannot be completely excluded and 
has to be considered.  
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Figure 12. Impact of 2DG and diclofenac on glucose metabolism of stimulated human CD4
+
 and CD8
+
 T 
lymphocytes 
(A/B) Glucose and (C/D) lactate levels are measured enzymatically in culture supernatants after 72 hours of 
stimulation; Untreated and 2DG n=4, diclo n=3 (P value 0.05>*>0.01>**>0.001>***; treatment induced changes 
are analyzed with ANOVA and post-hoc by Tukey´s multiple comparison test) 
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Table 1. Impact of 2DG and diclofenac on stimulated CD4
+
 and CD8
+
 T cells after 7 days 
Glucose and lactate levels were measured enzymatically in culture supernatants after 7 days of stimulation; mean 
diameter was determined by CASEY system; Measurement of interferon ɣ concentrations was performed by 
ELISA (P value 0.05>*>0.01>**>0.001>***, treatment induced changes were analyzed with ANOVA and post-hoc 
by Tukey´s multiple comparison test) 
7 days  untr. 
1 mM  
2DG 
5 mM  
2DG 
10 mM  
2DG 
0.1 mM 
diclo 
0.2 mM 
diclo 
glucose 
consumption 
[mM] 
CD4+ 
 
7.7 ± 
0.7 
(n=8) 
5.6 ± 
1.0 
(n=5) 
0.2 ± 
0.2*** 
(n=5) 
-0.4 ± 
0.3*** 
(n=4) 
6.3 ± 
0.7 
(n=8) 
3.9 ± 
0.6** 
(n=8) 
CD8+ 
6.5 ± 
0.9 
(n=7) 
5.2 ± 
2.6 
(n=5) 
-0.1 ± 
0.2*** 
(n=5) 
-0.5 ± 
0.4*** 
(n=4) 
5.0 ± 
0.9 
(n=7) 
2.9 ± 
1.2* 
(n=7) 
lactate 
secretion [mM] 
CD4+ 
20.1 ± 
1.3 
(n=9) 
13.3 ± 
2.1 
(n=4) 
2.0 ± 
0.2*** 
(n=4) 
1.3 ± 
0.1*** 
(n=4) 
15.6 ± 
1.5 
(n=8) 
11.3 ± 
1.6*** 
(n=8) 
CD8+ 
17.9 ± 
1.8 
(n=8) 
13.6 ± 
2.4 
(n=5) 
2.2 ± 
0.2*** 
(n=5) 
1.3 ± 
0.1*** 
(n=4) 
11.9 ± 
1.8 
(n=7) 
9.1 ± 
2.0** 
(n=7) 
mean diameter 
[µm] 
CD4+ 
9.4 ± 
0.1 
(n=10) 
9.5 ± 
0.1 
(n=4) 
9.1 ± 
0.2 
(n=4) 
8.6 ± 
0.1** 
(n=4) 
9.5 ± 
0.1 
(n=8) 
9.4 ± 
0.1 
(n=8) 
CD8+ 
9.1 ± 
0.1 
(n=9) 
9.4 ± 
0.1 
(n=4) 
9.3 ± 
0.1 
(n=4) 
9.0 ± 
0.1 
(n=4) 
9.1 ± 
0.1 
(n=7) 
8.8 ± 
0.1 
(n=7) 
viability [%] 
CD4+ 
71.3 ± 
5.4 
(n=4) 
91.1 ± 
1.6** 
(n=4) 
83.9 ± 
2.6 
(n=4) 
75.6 ± 
2.3 
(n=4) 
85.8 ± 
1.1 
(n=3) 
77.5 ± 
2.9 
(n=3) 
CD8+ 
72.6 ± 
5.2 
(n=4) 
91.9 ± 
1.3* 
(n=4) 
85.2 ± 
1.5 
(n=4) 
76.8 ± 
2.4 
(n=4) 
86.1 ± 
2.2 
(n=3) 
72.1 ± 
6.8 
(n=3) 
interferon ɣ 
[pg/ml] 
CD4+ 
20.1 ± 
8.8 
(n=9) 
10.6 ± 
2.6 
(n=5) 
3.5 ± 
2.2 
(n=5) 
2.4 ± 
2.2 
(n=4) 
39.4 ± 
15.9 
(n=8) 
64.8 ± 
25.2 
(n=8) 
CD8+ 
44.2 ± 
13.0 
(n=8) 
20.3 ± 
3.9 
(n=5) 
15.3 ± 
3.1 
(n=5) 
12.9 ± 
3.8 
(n=4) 
113.7 ± 
60.9 
(n=7) 
156.1 ± 
66.1 
(n=7) 
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4.3.2.2 Cell growth, proliferation and viability 
 
Upon stimulation “on-blast” formation of T cells took place immediately. Treatment 
with 2DG impaired cell growth significantly in both subtypes and application of 10 mM 
2DG reduced cell size by up to 20 % (n = 4, data not shown). In contrast, neither 
CD4+ nor CD8+ T cell size was reduced by treatment with diclofenac (n = 3, data not 
shown). Only 10 mM 2DG exerted a persisting impact on CD4+ T cells up to 7 days 
(table 1). 
Within the first 72 hours, 2DG and diclofenac reduced proliferation in both 
subpopulations, but statistical significance was only reached in CD4+ T cells (fig. 
13A-D). In line with a reduced impact on glucose metabolism after day 3, the impact 
of 1 mM 2DG on proliferation was also diminished but still significant in CD4+ T cells. 
5 and 10 mM 2DG lowered proliferation strongly in both subpopulations reflecting a 
strong impact on glycolysis (fig. 13A/B). 0.1 mM diclofenac reduced cell number only 
significantly in CD4+ T cells, whereas 0.2 mM impaired proliferation in both 
populations (fig. 13C/D). However, the impact of diclofenac was more pronounced in 
CD4+ T cell cultures after 7 days (table 1).  
Glycolytic inhibition with 2DG had almost no impact on T cell viability and only 10 mM 
2DG affected CD4+ T cells significantly. Diclofenac treatment had no effect on T cell 
viability, which is in contrast to the leukemic cell line (fig. 13E/F). The drop in viability 
at the end of a stimulation period (after 7 days) observed in control cell cultures was 
not detected in treated cells. This might be the result of reduced lactic acid levels in 
cell cultures (table 1). 
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Figure 13. Impact of 2DG and diclofenac on proliferation and viability of stimulated human CD4
+
 and CD8
+
 T 
lymphocytes 
(A-D) cell number was determined by CASEY system and (E-F) viability by flow cytometry with Annexin V and 7-
AAD staining after 72 hours of treatment.  A untreated and 2DG n=4, diclo n=3; B untreated 3d n=4 and 7d n=9, 
2DG 3 and 7d n=4, diclo 3d n=3 and 7d n=7; C and D untreated and 2DG n=4, diclo n=3 (P value 
0.05>*>0.01>**>0.001>***; treatment induced changes were analyzed with ANOVA and post-hoc by Tukey´s 
multiple comparison test) 
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4.3.2.3 Impact on interferon ɣ and IL-2 production 
 
When treated with glycolytic inhibitors an opposite effect on interferon ɣ secretion 
was observed. 2DG treatment led to decreased interferon ɣ levels in a concentration 
dependent manner, whereas diclofenac had no inhibiting but even more a beneficial 
effect on interferon ɣ secretion (fig. 14A/B).  
Interleukin 2 (IL-2) stimulates the proliferation of T cells and is secreted to a much 
lower extent by CD8+ than CD4+ T lymphocytes. While CD4+ T cells produced less 
IL-2 under 2DG treatment, 2DG had no impact on IL-2 secretion in CD8+ T cells. 
Diclofenac exerted only a marginal effect on IL-2 secretion in T lymphocytes (fig. 
14C/D). 
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Figure 14. Impact of 2DG and diclofenac on interferon ɣ and interleukin 2 secretion of stimulated human CD4
+ 
and CD8
+
 T lymphocytes 
(A/B) Interferon ɣ and (C/D) IL-2 are measured after 48 hours of stimulation in culture supernatants by Elisa; A 
untreated n=6, 2DG n=4, 0.1 mM diclo n=5, 0.2 mM diclo n=6; B untreated n=6, 2DG n=4, diclo n=3; C untreated 
and 2DG n=4, diclo n=3; D n=3; (P value 0.05>*>0.01>**>0.001>***, treatment induced changes are analyzed 
with ANOVA and post-hoc by Tukey´s multiple comparison test) 
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Another important cytokine mainly produced by CD4+ T cells is interleukin 10 (IL-10), 
which has an anti-inflammatory and regulating effect on the immune response 
suppressing T cell activity. 0.1 mM diclofenac significantly increased IL-10 
production, whereas 2DG significantly reduced IL-10 secretion (table 2). 
 
Table 2. Impact of 2DG and diclofenac on IL-10 secretion of CD4
+
 T cells after 48 hours  
IL-10 was measured in culture supernatants after 48 hours of stimulation by ELISA; A untreated n=6, 2DG n=4, 
0.1 mM diclo n=5, 0.2 mM diclo n=6; B untreated n=6, 2DG n=4, diclo n=3; C untreated and 2DG n=4, diclo n=3; 
D n=3; (P value 0.05>*>0.01>**>0.001>***, treatment induced changes were analyzed with ANOVA and post-hoc 
by Tukey´s multiple comparison test) 
 
 
To sum up, cytokine production was only affected by 2DG treatment, but not by 
diclofenac. As both inhibitors reduced glycolysis to a comparable extent, these 
results strongly indicate adverse side effects of 2DG.  
 
4.3.2.4 Expression of the activation-related surface markers CD137, CD25 and 
CD95 
 
CD137, a member of the tumor necrosis factor (TNF) receptor family, is expressed 
mainly on activated CD8+ T cells acting as a co-stimulatory molecule. After 48 hours 
of stimulation CD8+ T cells showed - compared to CD4+ T cells (fig. 15A) - a highly 
increased expression (fig. 15D). Application of 2DG or 0.2 mM diclofenac slightly 
lowered CD137 expression in CD8+ T cells, whereas its expression was not affected 
by both inhibitors in CD4+ T cells.  
As a marker of activated T cells CD25, part of the IL-2 receptor, was measured after 
seven days of stimulation and, in contrast to CD137, less expressed in CD8+ (fig. 
15E) compared to CD4+ T cell cultures (fig. 15B). Both subpopulations were 
IL-10 
[pg/ml]; 
(n=3) 
untreated 1 mM 
2DG 
5 mM 
2DG 
10 mM 
2DG 
0.1 mM 
diclofenac 
0.2 mM 
diclofenac 
CD4+  4716 ± 
103.5 
1472 ± 
247.6*** 
286.4 ± 
26.0*** 
121.1 ± 
16.1*** 
6590 ± 
797.2* 
4743 ± 
360.5 
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negatively affected by 2DG treatment with 5 and 10 mM, whereas diclofenac had 
only a marginal impact.  
CD95, better known as Fas receptor, is expressed by mature T cells and, when 
bound by the Fas ligand, induces apoptosis. Measured after seven days of 
stimulation CD95 was not significantly affected by both glycolytic inhibitors (fig. 
15C/F).  
 
 
 
In summary, both glycolytic inhibitors exerted only marginal effects on the expression 
of activation related surface markers. 
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Figure 15. Impact of 2DG and diclofenac on expression of surface markers CD137, CD25 and CD95 of stimulated 
human CD4
+
 and CD8
+
 T lymphocytes 
Cells were stained for flow cytometry  with anti-CD137 (after 48 hours), anti-CD25 and anti-CD95 antibodies (after 
7 days); bars show the median fluorescence ± SEM; A quiescent n=7, untreated and diclo n=6, 2DG n=3; B and 
C quiescent n=7, untreated n=4, 2DG and diclo n=3; D untreated n=6, 2DG n=4, diclo n=3; D quiescent and 
untreated n=6, 1mM 2DG n=2, 5 and 10 mM 2DG n=3, 0.1 mM diclo n=4, 0.2 mM diclo n=5; E quiescent n=7, 
untreated n=5, 1 mM 2DG n=4, 5 and 10 mM 2DG n=3, diclo n=4;  F quiescent n=6, untreated n=5, 1 and 5 mM 
2DG n=4, 10 mM 2DG n=3, diclo n=4; (P value 0.05>*>0.01>**>0.001>***, treatment induced changes were 
analyzed with ANOVA and post-hoc by Tukey´s multiple comparison test) 
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4.3.3 Impact on restimulated human T cells 
 
After characterizing the impact of anti-glycolytic drugs on the activation of freshly 
isolated CD4+ and CD8+ T cells, the effects of equal drug concentrations on fully 
stimulated immune cells were investigated. Restimulated T cells display an increased 
glycolytic activity thereby the metabolic profile is more comparable to tumor cells. 
The experimental set-up was the same as applied to stimulated T cells. Additionally 
the impact of 0.1 and 0.2 mM diclofenac on T cells expanded for two weeks and 
restimulated once again, representing a long-term cell culture, were investigated. 
During this third stimulation period we analyzed only the impact of diclofenac, which 
showed – in contrast to 2DG treatment – promising results concerning preserved 
effector function of T cells under treatment.  
 
4.3.3.1 Glucose metabolism 
 
2DG and diclofenac exerted a significant impact on glycolysis in restimulated T cells, 
however the inhibition was less pronounced compared to stimulated T cells. After 
restimulation 1 mM 2DG reduced glucose consumption by 50 % (in contrast to 80 % 
during stimulation) and 5 mM treated cells exhibited an uptake of 20 % of control 
cultures (during stimulation a complete block was observed). Only 10 mM 2DG 
blocked glucose consumption utterly within the first 72 hours (data not shown).  
Effects of diclofenac were also less pronounced and 0.1 mM treated cells consumed 
70 % (fist stimulation 50 %) of initially available medium glucose and cells treated 
with 0.2 mM 50 % compared to 25 % during the first stimulation in both T cell 
populations (data not shown).  
Reduction of lactic acid secretion by both inhibitors was significant in CD4+ T cells, 
whereas CD8+ T cells again were affected only by high-dose 2DG application (fig. 
16A/B).     
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4.3.3.2 Cell growth, proliferation and viability 
 
The slight increase in cell size during restimulation (10-15 %) was significantly 
reduced only by the application of 5 mM and 10 mM 2DG in CD4+ T cells. Diclofenac 
had only marginal effect on the diameter of both subtypes (data not shown).  
Restimulated T cells showed a high proliferative capacity and 5 mM 2DG, 10 mM 
2DG and 0.2 mM diclofenac reduced proliferation significantly in both populations, 
whereas 1 mM 2DG impeded proliferation only in CD8+ T cell cultures (fig. 17A/B). 
This is in line with the reduced impact of glycolytic inhibition on restimulated T 
lymphocytes. 
Restimulation had no effect on viability and untreated cultures showed a viability of 
90 %. Only 10 mM 2DG reduced viability significantly (fig. 17C/D).   
 
 
 
 
 
 
0
7
14
21
***
***
***
**
***
untreated
1 105 0.20.1
2DG diclo
medium lactate
la
c
ta
te
 c
o
n
c
e
n
tr
a
ti
o
n
 [
m
M
]
0
7
14
21
* **
1 5 10 0.1 0.2
2DG diclo
medium lactate untreated
la
c
ta
te
 c
o
n
c
e
n
tr
a
ti
o
n
 [
m
M
]
CD4+ CD8+
A B
Figure 16. Impact of 2DG and diclofenac on lactate secretion of restimulated human CD4
+
 and CD8
+
 T 
lymphocytes 
Lactate levels were measured enzymatically in culture supernatants after 72 hours. Untreated and 2DG n=4, diclo 
n=3 (P value 0.05>*>0.01>**>0.001>***, treatment induced changes were analyzed with ANOVA and post-hoc by 
Tukey´s multiple comparison test) 
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4.3.3.3 Interferon ɣ, IL-2 and IL-10 secretion 
 
The remarkable, distinct effects of 2DG and diclofenac were observed again in 
restimulated T cells. 2DG reduced interferon ɣ secretion, whereas diclofenac 
preserved or marginally increased secretion (fig. 18A/B).  
IL-2 concentrations of CD4+ T cell cultures were not significantly affected by a 2 DG 
treatment (data not shown, n=4). In contrast, both doses of diclofenac led to an 
increase in supernatant IL-2 concentration of CD4+ T cells, which was even 
significant in the case of 0.1 mM diclofenac (data not shown, n=3). Upon 48 hours of 
restimulation, CD8+ T cells secreted no IL-2 (data not shown). 
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Figure 17. Impact of 2DG and diclofenac on proliferation and viability of restimulated human CD4
+
 and CD8
+
 T 
lymphocytes 
(A/B) Cell number was determined by CASEY system after 72 hours; (C/D) viability was analyzed by flow 
cytometry with Annexin V and 7-AAD staining measurement. Untreated and 2DG n=4, diclo n=3 (P value 
0.05>*>0.01>**>0.001>***, treatment induced changes were analyzed with ANOVA and post-hoc by Tukey´s 
multiple comparison test) 
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Similar to interferon ɣ, 2DG reduced IL-10 production significantly by 60 % (1 mM), 
90 % (5 mM) and 95 % (10 mM, n=3, data not shown), whereas diclofenac exerted 
no significant effects.   
 
 
 
 
 
 
 
 
 
 
 
 
4.3.3.4 Impact of diclofenac on two-times restimulated T cells 
 
A second restimulation resulted in a reduced glycolytic activity. Especially CD8+ T 
cells consumed less than 20 % of initial medium glucose resulting in reduced lactate 
secretion. Treatment with diclofenac had only a marginal inhibitory effect on 
metabolism of CD8+ T cells. In contrast, CD4+ T cells were glycolytically more active 
and the impact of diclofenac was significant (table 3). 
After 72 hours mean diameters of two times restimulated cells were comparable to 
one time restimulated cells and diclofenac application had no observable effect (table 
3). 
The proliferation capability and cell number of untreated, two-times restimulated T 
cells was reduced and inhibition of proliferation by 0.2 mM diclofenac was significant 
in CD4+ T cells (table 3).  
Viability was again not affected by the treatment with diclofenac (table 3).  
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Figure 18. Impact of 2DG and diclofenac on interferon ɣ secretion of restimulated human CD4
+
 and CD8
+
 T 
lymphocytes 
Analysis of interferon ɣ concentrations was performed by ELISA after 48 hours of restimulation; Untreated and 
2DG n=4, diclo n=3 (P value 0.05>*>0.01>**>0.001>***, treatment induced changes were analyzed with ANOVA 
and post-hoc by Tukey´s multiple comparison test) 
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Interferon ɣ secretion was already low after restimulation and further restimulated 
cells only produced 70 % (CD4+) and 50 % (CD8+) of levels detected in one time 
restimulated cell supernatants displaying an exhausted phenotype. However, even in 
multiple stimulated T cells diclofenac exerted no significant effect on interferon ɣ 
secretion (table 3). 
 
Table 3. Impact of 2DG and diclofenac on two times re-stimulated CD4
+
 and CD8
+
 T cells  
Glucose and lactate levels were measured enzymatically in culture supernatants; cell number and mean diameter 
were determined by CASEY system; Measurement of interferon ɣ concentrations were performed by ELISA, 
viability was analyzed by flow cytometry with Annexin V and 7-AAD staining (P value 0.05>*>0.01>**>0.001>***, 
treatment induced changes were analyzed with ANOVA and post-hoc by Tukey´s multiple comparison test) 
 
 
 
 
 
 
 
72 hours  untreated 0.1 mM diclo 0.2 mM diclo 
glucose 
consumption 
[mM] 
CD4+ (n=4) 4.7 ± 0.4 2.6 ± 0.3* 1.6 ± 0.7** 
CD8+ (n=2) 1.7 1.0 0.7 
lactate [mM] 
CD4+ 13.5 ± 1.3 8.5 ± 0.8* 7.1 ± 0.8** 
CD8+ 9.5 5.8 5.3 
cell number [x 
106/ml] 
CD4+ 1.1 ± 0.1 0.8 ± 0.1 0.6 ± 0.1** 
CD8+ 0.8 0.6 0.5 
mean diameter 
[µm] 
CD4+ 10.7 ± 0.3 10.7 ± 0.3 10.7 ± 0.3 
CD8+ 9.8 9.7 9.4 
viability [%] 
CD4+ 88.8 ± 1.2 81.3 ± 4.6 79.6 ± 2.8 
CD8+ 72.6 72.3 68.4 
interferon ɣ 
[pg/ml] 
CD4+ 669.9 ± 234.0 447.8 ± 235.7 567.2 ± 220.2 
CD8+ 307.9 268.0 283.7 
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4.3.4 Impact of continuous diclofenac exposure 
 
Therapeutic benefits of medical approaches depend – among other factors – on long 
term toleration by the patient. Because of this the hereinafter described experiments 
were performed to analyze the effect of permanent anti-metabolic treatment by 
diclofenac on human T cells.  
 
T cells maintained their highly glycolytic phenotype during 14 days of culture. Within 
the two weeks of continuous application, diclofenac reduced glucose uptake of CD4+ 
T cells by 30 % (0.1 mM, n=5) and 60 % (0.2 mM, n=5). CD8+ T cells in contrast 
were impaired stronger by 65 % (0.1 mM, n=3) and 80 % (0.2 mM, n=3). However, 
differences between both subpopulations did not reach statistical significance (data 
not shown). Similar observations were made with respect to lactate secretion (fig. 
20A). While both untreated subpopulations produced nearly equal amounts of 
lactate, the reduction was more effective in CD8+ T cell cultures.  
 
Diclofenac had no impact on cell size after 14 days of continuous treatment (data not 
shown). Proliferation of CD4+ T cells was not affected by 0.1 mM diclofenac, while 
CD8+ cell number was reduced by 40 % (fig. 20B). The effect of 0.2 mM diclofenac 
was similar in both T cell populations. Furthermore, diclofenac treatment had no 
negative impact on viability in long-term cultures (fig. 20C).  
 
Analyzing cytokine production revealed that even a long-term treatment with 
diclofenac did not affect IFNɣ levels (fig. 20D). Moreover, no impact on CD25 
expression was detected and we even observed a significantly increased expression 
in CD4+ T cells continuously treated with 0.2 mM diclofenac (data not shown, CD4+ 
n=5, CD8+ n=3). CD95 expression was increased by 50 % in CD4+ and by 75 % in 
CD8+ T cells under diclofenac treatment (data not shown, CD4+ n=4, CD8+ n=3). 
Statistical significance was not reached however a clear trend was observed. 
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Figure 19. Impact of diclofenac on lactate concentration, proliferation, viability and interferon ɣ secretion of 
continuously treated human CD4
+
 and CD8
+
 T lymphocytes 
(A) lactate levels were measured enzymatically in culture supernatants after 14 days of continuous diclofenac 
application; (B) cell number was determined by CASEY system; (C) viability was analyzed by flow cytometry with 
Annexin V and 7-AAD staining; (D) measurement of interferon ɣ concentrations was performed by ELISA A, C 
and D CD4
+
 n=5, CD8
+
 n=3, B CD4
+
 untreated n=6, CD4
+
 diclo n=5, CD8
+
 n=3 (P value 
0.05>*>0.01>**>0.001>***, treatment induced changes were analyzed with ANOVA and post-hoc by Tukey´s 
multiple comparison test) 
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4.3.5 Impact on a mixed leukocyte reaction (MLR) 
 
In all aforementioned experiments T cells were stimulated with anti-CD3/CD28 
beads, which represent a strong but perhaps not physiologic activation stimulus for T 
cells. To apply a more physiologic stimulus, T cells were also activated with mature 
dendritic cells in an allogeneic setting and the impact of diclofenac and 2DG on T cell 
populations was investigated. In this set-up pre-matured dendritic cells (mDCs) of 
one donor are incubated together with CD4+ lymphocytes of another donor. In this 
setting, however, additional effects of 2DG and diclofenac on DCs cannot be 
completely excluded. 
Glucose and lactate concentrations measured after one week of stimulation showed 
two major results: (i) control cells were highly glycolytic and secreted large amounts 
of lactate and (ii) the anti-glycolytic treatment was effective. As a control culture 
lymphocytes alone were analyzed again concerning glucose consumption and lactate 
secretion after 7 days and showed negligible activity (table 4). 
Proliferation was strongly affected by 2DG and a highly significant abatement was 
observed after 7 days comparable to anti-CD3/CD28 activated T cells. Also 
diclofenac impaired proliferation effectively, but to a less extent. While cell number 
was strongly diminished by 2DG and diclofenac the mean diameter only dropped 
slightly under 2DG treatment and diclofenac showed no impact, comparable to the 
results gained in anti-CD3/CD28 activated T cells (table 4).   
After 7 days of co-cultivation about 90 % of untreated lymphocytes were viable. While 
significant reduction of viability was obtained by 5 mM 2DG treatment, diclofenac in 
contrast led only to a slight and not significant reduction (table 4). 
CD25 expression was higher than in bead-stimulated cultures and anti-glycolytic 
treatments with 2DG strongly reduced the expression of CD25. Especially 5 mM 2DG 
diminished CD25 expression significantly to the level found in unstimulated 
lymphocytes (table 4).  
In addition CD95 expression was reduced by 2 DG (significant by 5 mM 2DG) and in 
contrast diclofenac raised the median fluorescence however not significant (table 4).  
The interferon ɣ secretion of 2DG treated co-cultures was almost completely 
inhibited, whereas diclofenac led to maintained or even increased production.  
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IL-2 and IL-10 were produced to a less extent compared to anti-CD3/CD28 activated 
T cells. Neither 2DG nor diclofenac exert significant impact on IL-2 and IL-10 
secretion (table 4). 
 
Table 4. Impact of 2DG and diclofenac on CD4
+
 lymphocytes activated in a mixed leukocyte reaction (MLR)  
Glucose and lactate levels were measured in culture supernatants after 7 days of allogenic activation via MLR; 
Cell number and mean diameter were determined by CASEY system; Measurement of interferon ɣ/IL-2/IL-10 
concentrations were performed by ELISA; Viability was analyzed by Annexin V and 7-AAD staining and surface 
markers by anti-CD25/-CD95 staining for flow cytometry (P value 0.05>*>0.01>**>0.001>***, treatment induced 
changes were analyzed with ANOVA and post-hoc by Tukey´s multiple comparison test) 
 
after 7 days untreated 
1 mM 
2DG 
5 mM 
2DG 
0.1 mM 
diclo 
0.2 mM 
diclo 
only 
CD4+ 
glucose 
consumption  
[mM] 
(n=4) 
8.4 ± 0.1 
0.5 ± 
0.3*** 
-0.8 ± 
0.3*** 
4.5 ± 
0.8** 
1.6 ± 
1.1*** 
-2.1 ± 
0.6 
(n=3) 
lactate 
secretion [mM] 
(n=4) 
 
22.2 ± 0.8 
3.0 ± 
0.9*** 
1.3 ± 
0.0*** 
12.0 ± 
1.3*** 
 
6.1 ± 
1.0*** 
 
1.1 ± 0.1 
(n=3) 
proliferation 
[10^6/ml] 
(n=4) 
2.9 ± 0.2 
0.7 ± 
0.1*** 
0.5 ± 
0.1*** 
1.7 ± 
0.2*** 
1.1 ± 
0.1*** 
0.4 ± 0.2 
(n=2) 
mean diameter 
[µm] 
(n=4) 
10.3 ± 0.3 9.2 ± 0.4 
8.3 ± 
0.1** 
10.3 ± 
0.3 
10.0 ± 
0.3 
7.5 ± 0.2 
(n=2) 
viability [%] 
(n=4) 
89.6 ± 0.8 
76.5 ± 
1.9 
56.1 ± 
9.0*** 
87.7 ± 
1.6 
82.5 ± 
2.3 
87.0 ± 
4.0 
(n=2) 
CD25 [median 
fluorescence] 
(n=4) 
263.0 ± 
72.9 
73.3 ± 
44.3 
4.0 ± 
0.4* 
251.7 ± 
66.1 
193.1 ± 
23.2 
3.0 ± 0.1 
(n=7) 
CD95 [median 
fluorescence] 
(n=4) 
72.1 ± 6.8 
60.6 ± 
13.3 
8.0 ± 
2.4*** 
80.6 ± 
4.7 
87.5 ± 
8.3 
5.7 ± 1.0 
(n=7) 
Results 
 
62 
 
IFNɣ [pg/ml] 
(n=4) 
83.9 ± 9.7 5.1 ± 3.4 n.d. 
95.5 ± 
24.3 
85.4 ± 
41.2 
n.d. 
(n=1) 
IL-2 [pg/ml] 
605.0 ± 
196.7 
(n=4) 
543.6 ± 
243.8 
(n=3) 
423.7 ± 
350.3 
(n=2) 
474.4 ± 
193.0 
(n=3) 
516.3 ± 
234.0 
(n=3) 
100.9 ± 
87.9 
(n=3) 
IL-10 [pg/ml] 
(n=4) 
10.1 ± 4.3 3.5 ± 3.1 8.3 ± 4.9 
12.9 ± 
6.2 
14.4 ± 
5.9 
n.d. 
(n=1) 
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5. Discussion 
5.1 Metabolic features of malignant and primary human T cells 
 
Upregulated glycolysis despite a sufficient oxygen supply (= Warburg effect) is a 
metabolic feature of malignant cells, which is well known for many years and found in 
both, solid tumors and leukemia (6, 31). Tumor cells degrade glucose mainly to 
lactate, which is secreted in co-transport with a proton, resulting in lactate 
accumulation and concomitant acidification, referred as lactic acid, in the 
microenvironment of solid tumors. This glycolytic phenotype is shown to correlate 
directly with a poor prognosis. Patients suffering from hepatocellular carcinoma with 
a high GLUT1 expression reveal a significantly reduced survival rate compared to 
carcinomas with a low GLUT1 expression (136). Similar results are found with regard 
to the expression of lactate dehydrogenase (LDH) in melanoma patients (137) as 
well as for MCT1 expression in patients with bladder carcinoma (138) respectively 
MCT4 expression in oral squamous cell carcinoma (139).  
In line, high extracellular lactate levels have a negative impact on patient prognosis, 
shown for cervix carcinoma by Walenta et al. (140). Several reasons are responsible 
for its pro-tumorigenic effects. Lactate exposure enhances mobility of tumor cells by 
promoting metastasis and cell spread (140–143). Moreover, lactic acid has profound 
effects on immune cell function. Dietl et al. demonstrated, that extracellular lactic acid 
reduces tumor necrosis factor α (TNF-α) secretion of monocytes thereby 
compromising the immune function (68). Furthermore, tumor derived lactate acts as 
a recruiting signal to tissue macrophages, polarizes a M2 phenotype (so called 
tumor-associated macrophages, TAMs) and induces the expression of vascular 
endothelial growth factor (VEGF) and arginase 1 (Arg1) shown by Colegio et al. 
Resulting neovascularization and nutrient provision promotes tumor growth (69). In 
addition, cytotoxicity and cytokine secretion of T cells is impeded in a lactic acid-rich 
milieu most likely due to intracellular accumulation and disturbed lactate efflux (66). 
Recently, Brand et al. proved a direct link between tumor-derived lactic acid and the 
inhibition of tumor immunosurveillance by T and NK cells in vivo (67).  
Given that glucose consumption promotes tumor proliferation while increasing lactate 
levels impede the anti-tumor immune response, inhibition of tumor glycolysis is a 
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promising therapeutic approach. Several anti-glycolytic substances are currently 
under investigation and clinical trials have been initiated (144). Furthermore, 
synergistic effects of anti-angiogenic antibodies or conventional chemotherapeutic 
drugs in combination with anti-glycolytic substrates have already been proven. After 
a short period of initial regression, breast cancer cells for instance resume their 
growth under the treatment with sunitinib, a multi-targeted inhibitor of the receptor 
tyrosine kinase, due to metabolic reprogramming towards the anaerobic glycolysis. 
The combinatorial treatment by sunitinib with glycolytic inhibitors or knock-out of 
MCT4 prevents the recurrence of the tumor (145). A similar effect is shown for the 
hexokinase inhibitor 2DG which sensitizes the acute lymphoblastic leukemia cells to 
the treatment with prednisolone (146) and re-sensitizes glucocorticoid resistant cells 
to dexamethasone (63).  
 
However, anti-glycolytic treatment might impede T cell function, which is considered 
as important for the anti-tumor immune response and patient survival. Numerous 
studies point out, that the activation of murine bulk T lymphocytes results in an 
upregulated glycolysis, which provides biomass and energy and is inevitable for 
proliferation and effector function such as IFNɣ secretion (122, 147–149). IFNɣ is of 
special importance for the anti-tumor immunity as it exerts several immunosupportive 
effects. The upregulation of MHC I expression on tumor cells resulting in a stronger 
immunogenicity and increase in sensitivity to cytotoxic T cells is described (81). 
Furthermore, IFNɣ activates macrophages of the M1 phenotype, which are capable 
of killing tumor cells. The key role of interferon is underlined by the fact that the 
deficiency of this cytokine or appropriate receptors leads to increased tumor 
incidence (81). In murine T cells, IFNɣ translation is reported to strongly depend on 
glucose supply, whereas IL-2 secretion is not affected by impaired glycolysis (113, 
118, 120, 150). Accordingly, the inhibition of glycolysis or glucose starvation leads to 
a restricted effector function of murine T cells (120). Considering those 
consequences of an anti-glycolytic therapy, it is surprising, that only little is known 
about the link between metabolism, cell cycle progression and effector functions in 
human T cells (3, 94, 95). Therefore, we analyzed the glucose metabolism in 
stimulated human CD4+ and CD8+ T cells in relation to effector functions. 
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Upon stimulation T cells grow and produce cytokines and after a 48 hour period of 
cell growth (“on-blast” formation), stimulated and restimulated human CD4+ and 
CD8+ T cells start to proliferate. During the first 24 hours of stimulation glucose 
metabolism is only marginally elevated in both populations, beyond 24 hours 
glycolysis is increased and a highly glycolytic state is achieved beyond 48 hours. 
This general pattern is observed in stimulated and restimulated CD4+ and CD8+ T 
cells, although glycolytic activity is higher in restimulated T cells. Generally, CD4+ 
lymphocytes slightly outperform CD8+ lymphocytes in terms of proliferation and 
glucose metabolism. Interferon ɣ is secreted by T cells immediately upon activation 
(quiescent cells do not secret any IFNɣ) thus independently of glucose consumption. 
Despite continuous stimulation and persistent glucose uptake, measurable IFNɣ 
concentrations drop sharply beyond 48 hours. Thus a direct link between glycolysis 
and IFNɣ secretion in human T lymphocytes seems unlikely, which would be a major 
difference between human and murine T cells.  
Taken together, our results show an upregulated glycolysis in proliferating human T 
cells, which is similar to tumor cells. Remarkably, important effector functions seem 
to be decoupled of glucose supply and consumption. Therefore, glycolytic inhibition 
should affect T cell proliferation, but not effector functions.  
 
5.2. Impact of an antiglycolytic treatment on leukemic versus primary T cells 
 
We examined the impact of 2DG and diclofenac on a human leukemic T-ALL cell line 
in comparison to primary human CD4+ and CD8+ T cells.  
The anti-metabolite 2-deoxyglucose is enzymatically phosphorylated to 2-
deoxyglucose-6-phosphate, which cannot be further metabolized and induces a 
feedback inhibition on glucose metabolism. Administration of 2DG can result in 
adverse side effects, e.g. dizziness, fatigue, confusion, anorexia and QT 
prolongation, depending on the administered concentration. However, Raez et al. did 
not find any severe adverse effects in ten solid tumor bearing patients, treated with 
2DG concentrations of up to 45 mg/kg (151). This corresponds to a serum 
concentration of 4.4 mM, based on an average patient with a bodyweight of 80 kg, 5 
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liters of blood volume and an assumed oral bioavailability of 100 %. In line, we 
performed our experiments in a range of 1 to 10 mM 2DG. 
In 2013 our group showed that diclofenac, a non-steroidal anti-inflammatory drug 
(NSAID), exerts an inhibitory effect on lactate secretion and proliferation of several 
different tumor cell lines in vitro and reduces growth of murine B16 melanoma cells in 
vivo (91). Additionally diclofenac inhibits lactate formation as shown in a murine 
glioma model (152). This effect is due to blocked lactate transport by MCT1 and 
MCT4 resulting in reduced extracellular lactic acid concentrations and intracellular 
accumulation, which impedes glycolysis. As demonstrated by Holger Becker (TU 
Kaiserslautern, unpublished) already low concentrations of diclofenac significantly 
reduce the activity of MCT1 (Ki 1.45 ± 0.04 µM) and MCT4 (Ki 0.14 ± 0.01 µM). In 
contrast to 2DG, adverse drug reactions of diclofenac are rare and well-known (12 % 
of treated patients) (153). The most common side effects include a disturbed 
gastrointestinal system (abdominal pain, nausea, peptic ulceration), skin 
appearances (rash, urticarial, dermatitis), dizziness as well as renal (oliguria, 
proteinuria) and cardio-vascular symptoms (edema, hypertension) (154).   
 
The human childhood T-ALL cell line CCRF-CEM-C7H2 has a highly glycolytic 
phenotype. The available medium glucose is almost entirely taken up within 72 hours 
correlating with a strong increase in cell number. Application of 2DG or diclofenac 
reduces glycolysis and proliferation significantly and to a comparable extent by using 
5 mM 2DG or 0.2 mM diclofenac. These findings underline the importance of 
glycolysis-derived biomass for tumor expansion also in leukemic cells.  
In CD4+ and CD8+ T cell cultures 2DG also exerts a significant effect on glucose 
consumption and lactate secretion. Even the administration of the lowest dose of 1 
mM 2DG results in a nearly total glycolytic blockade within the first 72 hours. The 
anti-glycolytic effect of 1 mM 2DG on the glycolysis of CD4+ T cells is significantly 
stronger than the effect of 0.1 mM diclofenac and therewith represents a 
considerable difference to the impact on C7H2 tumor cells. This tendency can also 
be found in CD8+ T lymphocytes. However, cells that have been treated and 
restimulated for seven days seem to be less affected by 2DG treatment, which 
suggests a possible development of a compensatory mechanism. Although medium 
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exchange after 4 days should ensure constant concentrations, degradation of the 
drug cannot be completely excluded. Surprisingly, the impact of 2DG on T cell 
activation is despite a comparable glycolytic inhibition much stronger compared to 
diclofenac. On-blast formation is significantly affected by 2DG, whereas diclofenac 
has only slight effects on cell growth of both T cell populations. 2DG blocks 
proliferation almost entirely within the first 72 hours, whereas diclofenac treated cells 
are less affected. In line with our results on glucose deprivation (132), high dose 2DG 
almost completely block proliferation, whereas 0.1 mM diclofenac treated cells show 
an increase in cell number by about 50 %. Moreover, the activation induced 
expression of CD25 is significantly repressed by 2DG, but not by diclofenac 
treatment.  
Taken together, both substances effectively reduce the glucose metabolism of 
leukemic and primary human T cells. However, diclofenac has a more pronounced 
negative impact on tumor cells, but is better tolerated by primary human T cells and 
preserves proliferation and activation.   
 
Both glycolytic inhibitors reduce the viability of C7H2 cells, but a significant stronger 
effect of diclofenac was observed. A conceivable reason is the cytotoxic intracellular 
lactic acid accumulation by inhibition of monocarboxylate transporters. As shown by 
Barry and Eastman, intracellular acidification results in the activation of 
deoxyribonuclease II which leads to apoptosis and cell death (155). Nevertheless, 
further direct apoptosis inducing effects of diclofenac cannot be excluded. T cells 
treated with high doses diclofenac show, despite a similar impact on glycolysis, a 
totally preserved survival rate. In contrast, the application of 10 mM 2DG diminishes 
viability significantly and to a comparable extent in malignant and non-malignant T 
cells. Interestingly, beyond 72 hours of stimulation, viability of T cells is improved by 
the application of both anti-glycolytic agents, which may be due to the reduced 
extracellular, cytotoxic lactate levels compared to untreated cell cultures. As shown 
by Fischer et al. (66), lactic acid exerts a strong negative impact on T cell viability 
and effector functions in a concentration dependent manner. Accordingly, the 
therapeutic application of glycolytic inhibitor diclofenac directly reduces the viability of 
tumor cells while T cell viability is preserved or even increased by concomitantly 
reduced lactic acid secretion. 
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Along with the murine data, IFNɣ secretion of 2DG treated human T cells is reduced. 
Furthermore, the production of the cytokines IL-2 and IL-10 is compromised by the 
2DG treatment in CD4+ T cells, whereas the IL-2 secretion of CD8+ T cells is 
preserved. While glucose metabolism is impeded effectively by diclofenac, IFNɣ 
production is utterly preserved and stimulated CD8+ T cells treated with 0.2 mM even 
show significantly higher IFNɣ levels. Furthermore, IL-2 secretion is only marginally 
affected by diclofenac and not altered concentrations of IL-10 are found in CD4+ 
lymphocytes. On the basis of these results it seems irritating, that 2DG and 
diclofenac display such strong differences concerning the impact on T cell effector 
function despite comparable effects on glycolysis. Accordingly, a direct link between 
glucose metabolism and IFNɣ secretion in human T cells is not likely. This is 
supported by the fact, that also glucose starvation has no impact on cytokine 
secretion (132). Furthermore, oligomycin, an irreversible inhibitor of the mitochondrial 
ATP-synthase, has no effect on the IFNɣ production in human T cells as well (132). 
In further analysis we could show, that 2DG not only inhibits glycolysis but also 
blocks respiration. Although T cells showed some metabolic flexibility as glucose 
deprivation can be compensated by increased respiration, blocking of both pathways 
is deleterious for T cell function (132).  
As shown above, 2DG application compromises the early on-blast formation, 
proliferation and CD25 expression, which reflects an unstimulated, quiescent state of 
the treated cells. These findings support two hypotheses: 
 
(i) T cell activation depends at least on one energy and biomass delivering pathway  
(ii) Respiration and anaerobic glycolysis seem to be interchangeable and therewith 
compensatory 
 
The physiological activation of an adaptive immune response involves a multicellular 
process and in addition antigen-presenting cells are possible targets of an anti-
glycolytic therapy. To assure physiological relevance, we also examined the 
consequences of the 2DG and the diclofenac treatment on an allogenic mixed 
leukocyte reaction (MLR) of CD4+ T cells with dendritic cells (DCs). After 7 days of 
stimulation, the data acquired in anti-CD3/CD28 stimulated cells are nearly congruent 
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with MLR results. Nevertheless, additional impacts of 2DG and diclofenac on the 
maturation of dendritic cells cannot be excluded by our experiments.  
Due to the constant lactate secretion by tumor cells, a long-term application of 
diclofenac without compromising the patients´ immune system is mandatory to 
ensure sustainable therapeutic success. Therefore, we analyzed the impact of an 
uninterrupted diclofenac treatment on stimulated T cells. Even after 14 days of 
treatment diclofenac has no impact on the IFNɣ secretion, while a persisting, but 
significant effect on glucose metabolism is observed.  
 
Our results contrast murine data and several explanations could be responsible for 
those differences between human and murine cells: 
Murine IFNɣ secretion strongly depends on glucose metabolism, whereas low 
glucose conditions preserve IFNɣ production in humans (113, 119, 132). 
Furthermore, Datta et al. demonstrated, that the blockade of the mTOR pathway 
impedes T cell motility in addition to the expression of migration-related surface 
markers in the murine, but not in the human immune system (115).Thus it is likely, 
that human and murine cells differ in their immune cell metabolism more than 
expected.  
In addition, experimental conditions have to be considered. The experiments showing 
the link between glucose metabolism and IFNɣ production in the murine system are 
performed in medium without serum or applying dialyzed serum. In contrast, human 
T cells are cultivated in non-dialyzed, AB- or fetal calf serum (FCS) containing 
medium. To exclude impacts of the different experimental set-ups, further 
experiments are necessary. 
 
Based on our results it seems possible to apply anti-glycolytic drugs reducing lactate 
secretion by tumor cells while preserving immune cell effector functions, however at 
the expense of reduced T cell proliferation. 
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5.3 Outlook: Glycolytic inhibition complements immunotherapeutic approaches 
 
Immunotherapeutic approaches are one of the most promising and paradigm-shifting 
strategies against tumor burden. The application of so called checkpoint inhibitors 
results in the release of T cell anergy and leads to the destruction of tumor cells. 
Promising results are already achieved in metastatic melanoma (156), advanced 
squamous non-small cell lung cancer (NSCLC) (157) and several others (158, 159). 
The checkpoints CTLA-4 (cytotoxic T lymphocyte antigen 4) and PD-1 (programmed 
death 1) are receptors on the cell surface of T cells and negatively regulate their 
activation and proliferation upon binding by appropriate ligands (81). Those ligands, 
such as the B7 family and PD-ligand 1 and 2 (PD-L1/-L2), are not only upregulated in 
the course of inflammation to avoid a permanent and unrestricted stimulation (81), 
but are also expressed by tumor cells to suppress the response of invading T cells 
(160). Therefore, the blockade of those co-inhibitory receptors by antibodies like 
ipilimumab (Anti-CTLA-4) and nivolumab (Anti-PD-1) preserves and enhances the 
anti-tumor immune response. It turns out that especially combinations of CLTA-4- 
and PD-1-blockades are effective (81). However, after an initial strong response to 
checkpoint inhibition many patients develop treatment resistance (161). Furthermore, 
checkpoint inhibition results in strong and unrestricted immune response thus severe 
immune-related adverse effects (irAEs) have been observed. These include most 
importantly endocrinopathies (like hypophysitis or hypothyroidism), pneumonitis, 
colitis, skin appearances (like pruritus and vitiligo) as well as an increase of hepatic 
enzymes (162). Hence, the development of combinatorial treatment schemes 
lowering necessary concentrations of checkpoint inhibitors thus reducing possible 
irAEs and avoiding resistance is of major interest.  
The success of checkpoint inhibition seems to be connected with tumor glucose 
metabolism as a high concentration of serum lactate dehydrogenase A (LDH-A) 
correlates with a poor outcome upon PD-1 and CTLA-4 blockade (163, 164). Beside 
lactate accumulation also secretion of PGE2, which is detected in a variety of tumors 
and assumed to be a primary driver of carcinogenesis (165–168), limits immune cell 
function. In line, Zelenay et al. demonstrated that the non-selective COX-inhibitor 
Aspirin enhances the efficacy of immunotherapy by anti-PD-1 antibodies in 
BRAFV600E mutated melanoma cells. Interestingly, selective COX2-inhibitors (so-
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called coxibes) show a synergism with anti-PD1 treatment as well, albeit to a lesser 
extent. (169).  
Based on our data, we hypothesize, that diclofenac, an unselective COX1 and COX2 
inhibitor might be much more efficient in combination with checkpoint inhibitors, as it 
combines the benefits of reduced PGE2- and lactate secretion. Necessary 
concentrations are only marginally higher than achieved with commonly used daily 
administration of 100 mg per os (152). Additionally, diclofenac is bound to 99 % to 
serum albumin (153). To liberate diclofenac from albumin and therewith achieve 
higher effective concentrations a simultaneous administration of agents with stronger 
plasma protein binding could be discussed.  
 
Taken together, anti-glycolytic drugs are promising supplements in 
immunotherapeutic approaches. Especially diclofenac lends itself to the combination 
with checkpoint inhibitors and offers the following advantages over the application of 
comparable glycolytic inhibitors such as 2DG:  
 
 extensive therapeutic experiences and a manageable spectrum of adverse 
effects 
 a significantly reduced tumor cell viability, but sustained immune cell viability  
 preserved immune cell activation and effector functions while effectively 
reduced tumor lactate secretion 
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6. Conclusion 
 
Human T-ALL cells as solid tumor cells exhibit a metabolic phenotype characterized 
by an upregulated glucose uptake and lactate secretion despite sufficient oxygen 
supply (= Warburg effect). Stimulated and re-stimulated human T lymphocytes show 
a similar metabolic shift towards aerobic glycolysis. However, glucose metabolism is 
not elevated during the initial phase of stimulation when cell growth and cytokine 
production takes place. Thus, IFNɣ secretion seems to be decoupled from glucose 
consumption. Comparing the impact of glycolytic inhibition on primary and malignant 
lymphocytes reveals that glucose uptake and lactate secretion are reduced in 
malignant and non-malignant T cells. The glycolytic inhibitors 2-deoxyglucose and 
diclofenac effectively reduce proliferation in malignant and non-malignant 
lymphocytes. However, despite reduced glycolysis diclofenac treatment preserves 
effector functions as the secretion of IFNɣ. In contrast, the application of 2DG 
simultaneously impairs glycolysis and cellular respiration and thereby compromises T 
cell activation, proliferation and effector functions.  
This study demonstrates that the application of the anti-glycolytic drug diclofenac 
effectively impairs tumor glucose metabolism and viability, while T cell effector 
functions are totally preserved. Especially immune therapies (e.g. checkpoint 
inhibition) could benefit from these insights, as tumor derived lactic acid is a strong 
immunosuppressive metabolite fostering immune escape. 
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8. Appendix 
8.1 German abstract 
 
Auswirkungen einer anti-metabolischen Therapie auf leukämische und nicht-
maligne T-Lymphozyten 
 
Solide und leukämische Tumorzellen weisen einen bemerkenswerten Stoffwechsel 
auf: Trotz suffizienter Sauerstoffzufuhr zeigt sich eine gesteigerte Glykolyse mit 
erhöhtem Glukoseverbrauch und vermehrter Laktatsekretion (= aerobe Glykolyse). 
Diese Eigenschaft wird als Warburg-Effekt bezeichnet und ist weniger Ausdruck 
einer metabolischen Degeneration, sondern stellt vielmehr einen Wachstumsvorteil 
für Tumorzellen dar. Die in der Glykolyse anfallend Zwischenprodukte sind Bausteine 
für Zellwachstum und Proliferation.  Darüber hinaus übt Laktat, das glykolytische 
Endprodukt, einen immunsuppressiven Effekt aus und schränkt dadurch die 
Prognose von Tumorpatienten ein. Die Hemmung dieses charakteristischen 
Stoffwechsels mittels antiglykolytischer Substanzen tritt zunehmend in den Fokus der 
Forschung. Zu diesem Zwecke untersuchten wir die Auswirkungen von 2-
Deoxyglucose (2DG) und Diclofenac auf kindliche T-ALL Zellen. Beide Wirkstoffe 
hemmten die Glykolyse und Proliferation signifikant, jedoch wurde eine effektive 
Reduktion der Viabilität um bis zu 75 % nur unter Anwendung von Diclofenac 
beobachtet.  
Murine Daten deuten darauf hin, dass T-Lymphozyten bei Aktivierung ihren 
Stoffwechsel ebenfalls zu Gunsten der aeroben Glykolyse umstellen. Da nur wenige 
Daten bezüglich humaner T-Zellen vorliegen, analysierten wir in einem zweiten 
Schritt die Interaktion von Stoffwechsel und Effektorfunktionen in ein- und zweifach 
stimulierten CD4+ und CD8+ Spenderlymphozyten. Unmittelbar nach Aktivierung 
mittels anti-CD3/-CD28 Antikörpern war eine Sekretion von Interferon ɣ zu 
verzeichnen, wohingegen die Steigerung der Glykolyse und der Proliferation erst 
einem 48-stündigen Intervall des Zellwachstums („on-blast formation“) folgte.  
In vorausgehenden Experimenten wurde gezeigt, dass die Hemmung der Glykolyse 
zu einer erheblichen Störung der Effektorfunktionen und insbesondere der IFNɣ-
Sekretion durch murine T-Zellen führt. Diese Tatsache stellt eine große 
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Herausforderung für die klinische Anwendbarkeit von Glykolyseinhibitoren dar, zumal 
die Infiltration von Tumorgewebe durch funktionstüchtige T-Zellen grundlegend 
prognosebestimmend ist. In unseren Experimenten konnten wir zeigen, dass die 
Anwendung hoher Dosen von 2DG die Glykolyse und Proliferation nahezu komplett 
blockiert und die Sekretion wichtiger Effektorzytokine (IFNɣ, IL-2, IL-10) teils deutlich 
beeinträchtigt. In einigen experimentellen Konstellationen war sogar die Viabilität der 
humanen T-Zellen signifikant reduziert. Unter Berücksichtigung der ebenfalls 
vermindert exprimierten Reifungsmarker (CD137, CD25, CD95) muss von einer 
Beeinträchtigung der Aktivierbarkeit von humanen T-Zellen unter Anwendung von 
2DG ausgegangen werden.  
Im Gegensatz dazu konnte Diclofenac die Zytokinproduktion trotz vergleichbarer 
Auswirkungen auf die Glykolyse vollständig erhalten oder sogar steigern. Diese 
Ergebnisse widerlegen eine direkte Verknüpfung von Glukosestoffwechsel und 
sekretorischer Effektorfunktion humaner T-Lymphozyten. Bemerkenswert ist, dass 
Diclofenac keinen negativen Effekt auf die Viabilität der behandelten Zellen ausübte. 
Um die physiologische Relevanz unserer Ergebnisse zu bestätigen, analysierten wir 
anschließend die Auswirkungen beider Substanzen auf eine allogene 
Lymphozytenreaktion (= mixed leukocyte reaction, MLR). Die dabei erzielten 
Resultate konnten die Ergebnisse der anti-CD3/-CD28 stimulierten T-Zellen 
reproduzieren, wenn auch weitere Einflüsse von 2DG und Diclofenac auf die 
Antigen-präsentierenden Zellen hierbei nicht ausgeschlossen werden konnten. Der 
Erfolg einer medizinischen Therapie bemisst sich unter anderem an der 
Langzeitverträglichkeit und unsere Ergebnisse demonstrierten eine persistierende 
Effektorfunktion und Viabilität sogar unter eine kontinuierlichen, 14-tägigen 
Applikation von Diclofenac.  
Auf Grund dieser Erkenntnisse erscheint eine Kombinationstherapie von 
Glykolyseinhibitoren mit sogenannten Checkpoint-Inhibitoren vielversprechend. 
Checkpoint-Inhibitoren lösen eine gesteigerte, wenn auch ungerichtete 
Immunantwort von körpereignen Immunzellen gegen die Fremdantigen-
präsentierenden Tumorzellen aus. Diese Antwort wird jedoch durch vermehrt ins 
Tumormilieu sezernierte Milchsäure reduziert bzw. im Verlauf sogar vollständig 
unterdrückt, was einer Resistenzentwicklung gleich kommt. Eine Inhibition der 
Appendix 
 
92 
 
Laktatproduktion in Tumorzellen könnte diesen tumoreigenen Schutz vor einer 
zielgerichteten Immunabwehr aufheben. 
Weitere Experimente sind notwendig um die Interaktion von Metabolismus und 
Effektorfunktion humaner T-Zellen vollständig zu verstehen und die 
vielversprechenden antimetabolischen Therapien zur optimieren. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
93 
 
8.2 Abbreviations 
 
 2DG    2-deoxygluse 
 3´ UTR   three prime untranslated region 
 4E-BP1   eukaryotic initiation factor 4E binding protein 1  
 7-AAD   7-aminoactinomycin 
 AA    amino acid 
 acetyl-CoA   acetyl coenzyme A 
 ACL    ATP-citrate lyase 
 Akt    protein kinase B 
 AMPK   adenosine monophosphate activated protein kinase 
 ANOVA   analysis of variance 
 AP-1    activation protein 1 
 APC    antigen presenting cell 
 arg1    arginase 1 
 ASCT2   amino-acid transporter 2 
 ATP    adenosine triphosphate 
 Bad    Bcl-2-associated death promoter 
 Bak    Bcl-2 homologous antagonist killer 
 Bax    Bcl-2-associated X protein 
 Bcl-2    B cell lymphoma 2 
 bHLH    basic helix-loop-helix 
 Bim    Bcl-2-like protein 11 
 CD    cluster of differentiation 
 Cdk    cyclin dependent kinase 
 CO2    carbon dioxide 
 COX    cyclooxygenase 
 CREB    cyclic AMP response element-binding protein 
 CTL    cytotoxic T cell 
 CTLA-4   cytotoxic T lymphocyte antigen 4 
 CTP    cytidine triphosphate 
 DAG    diacyl glycerol 
 DC    dendritic cell 
 DCA    dichloroacetate 
 diclo    diclofenac 
 DNA    deoxyribonucleic acid 
 E-cadherin   epithelial cadherin 
 EGF    epidermal growth factor 
 EGFR    epidermal growth factor receptor 
 ELISA   enzyme-linked immunosorbent assay 
 ERK    extracellular-signal-regulated kinase 
 et al.    et altera 
 FACS    fluorescence-activated cell sorting 
 FCS    fetal calf serum 
 FasL    Fas ligand 
 fig.    figure 
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 FITC    fluorescein isothiocyanate 
 G1-phase   gap 1 phase 
 G6P    glucose-6-phosphate 
 G6PDH   glucose-6-phosphate dehydrogenase 
 GAPDH   glyceraldehyde-3-phosphate dehydrogenase  
 GATA3   trans-acting T-cell-specific transcription factor 
 GKS-3   glycogen synthase kinase 3 
 GLS    glutaminase 
 GLUT    glucose transporter 
 GM-CSF   granulocyte macrophage colony-stimulating factor 
 GTP    guanosine triphosphate 
 HIF1α    Hypoxia inducible factor 1α 
 HK    hexokinase 
 HRE    hypoxia-responsive elements 
 HRP    Streptavidin-Horseradish peroxidase 
 ICAM-1   intercellular adhesion molecule 1 
 i.e.    id est 
 IFNɣ    interferon ɣ 
 IGFR    insulin-like growth factor receptor 
 IL    interleukin 
 iNOS    inducible nitric oxide synthase 
 IP3    inositol-1,4,5-triphosphate 
 irAE    immune-related adverse effect 
 IRF4    interferon regulatory factor 4 
 IU    international unit 
 Jak    januskinase 
 LDH    lactate dehydrogenase 
 LFA-1    lymphocyte function-associated antigen 1 
 LPS    lipopolysaccharide 
 MACS   magnetic cell separation 
 MAPK   mitogen-activated protein kinase 
 Max    Myc-associated factor x    
 Mcl-1    induced myeloid leukemia cell differentiation protein 
 MCT    monocarboxylate transporter 
 Mdm2    mouse double minute 2 homolog 
 MEK    Mitogen/Extracellular signal-regulated kinase 
 MHC    major histocompatibility complex 
 MLR    mixed leukocyte reaction 
 mM    millimolar = millimole per liter 
 MMP    matrix metalloproteinase 
 mRNA   messenger RNA 
 mTORC1   mammalian target of rapamycin complex 1 
 Myc gene   myelocytomatosis gene 
 n    number (of samples) 
 NAD+/H   nicotinamide adenine dinucleotide 
 NADP+/H   nicotinamide adenine dinucleotide phosphate 
 NFAT    nuclear factor of activated T cells 
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 NFκB    nuclear factor κB 
 NK cells   natural killer cells  
 nm    nanometer 
 NO    nitric oxide 
 NSAID   non-steroidal anti-inflammatory drug 
 NSCLC   non-small cell lung cancer 
 Oct-4    octamer binding transcription factor 4 
 OXPHOS   oxidative phosphorylation 
 p21Cip    cyclin-dependent kinase inhibitor 1 
 p53    protein 53 
 PBMC   peripheral blood mononuclear cell 
 PBS    phosphate buffered saline 
 PD-1    programmed death 1 
 PDH    pyruvate dehydrogenase 
 PDK1    3-phosphoinositide dependent kinase 1 
 PD-L1   programmed death ligand 1 
 PE    phycoerythrin 
 PET-CT   Positron emission tomography – CT  
 PFK    phosphofructokinase 
 pg    picogram  
 PGE2    prostaglandin E2 
 PH    pleckstrin homology domain 
 pH    pondus hydrogenii 
 PI3K    phosphatidylinositol-3-kinase 
 PIP2    phosphatidylinositol-2-phosphate 
 PIP3    phosphatidylinositol-3-phosphate 
 PK    pyruvate kinase 
 PKC    protein kinase C  
 PLCɣ1   phospholipase C ɣ1 
 PPP    pentose phosphate pathway 
 Raf    rat fibrosarcoma 
 Ras    rat sarcoma 
 RB    retinoblastoma 
 RORɣt   RAR-related orphan receptor ɣt 
 ROS    reactive oxygen species 
 rpm    rounds per minute 
 RPTK    receptor protein tyrosine kinases 
 S6K1    S6 kinase 1 
 SEM    standard error of the mean 
 SCO2    cytochrome c oxidase 2 
 SKP2    S-phase kinase-associated protein 2 
 S-phase   synthesis phase 
 STAT    signal transducer and activator of transcription 
 T-ALL    T cell acute lymphoblastic leukemia 
 TAM    tumor associated macrophages 
 TCA cycle   tricarboxylic acid cycle 
 TCR    T cell receptor 
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 TGFβ    transforming growth factor β 
 Th cell    T helper cell 
 TIGAR   TP53-induced glycolysis and apoptosis regulator 
 TMB    tetramethylbenzidine 
 TNFα    tumor necrosis factor α 
 TP53    tumor protein p53 
 TSC 1/2   tuberous sclerosis complex 1/2 
 TTP    thymidine triphosphate 
 VEGF    vascular endothelial growth factor 
 αKG    α ketoglutarate 
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